{ "version": "2.2", "instance": { "ea0294983-20f_psyence.htm": { "nsprefix": "pbm", "nsuri": "http://www.psyencebiomed.com/20260331", "dts": { "inline": { "local": [ "ea0294983-20f_psyence.htm" ] }, "schema": { "local": [ "pbm-20260331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/sic/2025/sic-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "pbm-20260331_cal.xml" ] }, "definitionLink": { "local": [ "pbm-20260331_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "pbm-20260331_lab.xml" ] }, "presentationLink": { "local": [ "pbm-20260331_pre.xml" ] } }, "keyStandard": 229, "keyCustom": 220, "axisStandard": 24, "axisCustom": 5, "memberStandard": 30, "memberCustom": 80, "hidden": { "total": 214, "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 104, "http://www.psyencebiomed.com/20260331": 107, "http://xbrl.sec.gov/dei/2025": 3 }, "contextCount": 330, "entityCount": 1, "segmentCount": 120, "elementCount": 754, "unitCount": 6, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 620, "http://xbrl.sec.gov/dei/2025": 50, "http://xbrl.sec.gov/cyd/2025": 9, "http://xbrl.sec.gov/ecd/2025": 1 }, "report": { "R1": { "role": "http://www.psyencebiomed.com/role/DocumentAndEntityInformation", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "longName": "001 - Statement - Consolidated Statements of Financial Position", "shortName": "Consolidated Statements of Financial Position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:OtherCurrentReceivables", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "unique": true } }, "R3": { "role": "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement", "longName": "002 - Statement - Consolidated Statements of Net Income/(Loss) and Comprehensive Income/(Loss)", "shortName": "Consolidated Statements of Net Income/(Loss) and Comprehensive Income/(Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:SalesAndMarketingExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:SalesAndMarketingExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3", "longName": "003 - Statement - Consolidated Statements of Changes in Shareholders\u2019 Equity/(Deficit)", "shortName": "Consolidated Statements of Changes in Shareholders\u2019 Equity/(Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c9", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c9", "name": "ifrs-full:Equity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.psyencebiomed.com/role/ConsolidatedCashFlow", "longName": "004 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true }, "uniqueAnchor": { "contextRef": "c6", "name": "pbm:FairValueAdjustmentsOnPromissoryNote", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "unique": true } }, "R6": { "role": "http://www.psyencebiomed.com/role/NatureofOperationsandGoingConcern", "longName": "005 - Disclosure - Nature of Operations and Going Concern", "shortName": "Nature of Operations and Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.psyencebiomed.com/role/BasisofPresentation", "longName": "006 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.psyencebiomed.com/role/MaterialAccountingPolicies", "longName": "007 - Disclosure - Material Accounting Policies", "shortName": "Material Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.psyencebiomed.com/role/CriticalAccountingEstimatesandJudgements", "longName": "008 - Disclosure - Critical Accounting Estimates and Judgements", "shortName": "Critical Accounting Estimates and Judgements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCAC", "longName": "009 - Disclosure - Reverse Takeover Transaction with NCAC", "shortName": "Reverse Takeover Transaction with NCAC", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "pbm:ReverseTakeoverTransactionWithNcacTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:ReverseTakeoverTransactionWithNcacTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalents", "longName": "010 - Disclosure - Cash, Restricted Cash and Cash Equivalents", "shortName": "Cash, Restricted Cash and Cash Equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.psyencebiomed.com/role/DigitalAssets", "longName": "011 - Disclosure - Digital Assets", "shortName": "Digital Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfDigitalAssets", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfDigitalAssets", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.psyencebiomed.com/role/LoanReceivable", "longName": "012 - Disclosure - Loan Receivable", "shortName": "Loan Receivable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "pbm:LoanReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:LoanReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.psyencebiomed.com/role/PrepaidExpenses", "longName": "013 - Disclosure - Prepaid Expenses", "shortName": "Prepaid Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.psyencebiomed.com/role/Equipment", "longName": "014 - Disclosure - Equipment", "shortName": "Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociate", "longName": "015 - Disclosure - Psyence Labs Ltd. Investment and Investment in Associate", "shortName": "Psyence Labs Ltd. Investment and Investment in Associate", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfPsyenceLabsLtdInvestmentAndInvestmentInAssociate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfPsyenceLabsLtdInvestmentAndInvestmentInAssociate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.psyencebiomed.com/role/AccountsPayableandAccruedLiabilities", "longName": "016 - Disclosure - Accounts Payable and Accrued Liabilities", "shortName": "Accounts Payable and Accrued Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilities", "longName": "017 - Disclosure - Derivative Warrant Liabilities", "shortName": "Derivative Warrant Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.psyencebiomed.com/role/ShareCapital", "longName": "018 - Disclosure - Share Capital", "shortName": "Share Capital", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.psyencebiomed.com/role/OtherIncome", "longName": "019 - Disclosure - Other Income", "shortName": "Other Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.psyencebiomed.com/role/OtherExpense", "longName": "020 - Disclosure - Other Expense", "shortName": "Other Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.psyencebiomed.com/role/ConvertibleNoteLiability", "longName": "021 - Disclosure - Convertible Note Liability", "shortName": "Convertible Note Liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.psyencebiomed.com/role/PromissoryNotes", "longName": "022 - Disclosure - Promissory Notes", "shortName": "Promissory Notes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "pbm:PromissoryNotesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:PromissoryNotesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.psyencebiomed.com/role/ELOC", "longName": "023 - Disclosure - ELOC", "shortName": "ELOC", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "pbm:EquityLineOfCreditDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:EquityLineOfCreditDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrants", "longName": "024 - Disclosure - PIPE Financing - Private Placement and Warrants", "shortName": "PIPE Financing - Private Placement and Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.psyencebiomed.com/role/CapitalManagement", "longName": "025 - Disclosure - Capital Management", "shortName": "Capital Management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "pbm:CapitalManagementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:CapitalManagementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.psyencebiomed.com/role/TransactionswithRelatedParties", "longName": "026 - Disclosure - Transactions with Related Parties", "shortName": "Transactions with Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.psyencebiomed.com/role/IncomeTaxNote", "longName": "027 - Disclosure - Income Tax Note", "shortName": "Income Tax Note", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagement", "longName": "028 - Disclosure - Financial Instruments and Financial Risk Management", "shortName": "Financial Instruments and Financial Risk Management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.psyencebiomed.com/role/SubsequentEvents", "longName": "029 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R31": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R32": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.psyencebiomed.com/role/BasisofPresentationTables", "longName": "996001 - Disclosure - Basis of Presentation (Tables)", "shortName": "Basis of Presentation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.psyencebiomed.com/role/MaterialAccountingPoliciesTables", "longName": "996002 - Disclosure - Material Accounting Policies (Tables)", "shortName": "Material Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "pbm:ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACTables", "longName": "996003 - Disclosure - Reverse Takeover Transaction with NCAC (Tables)", "shortName": "Reverse Takeover Transaction with NCAC (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c0", "name": "pbm:ScheduleOfListingExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "pbm:ReverseTakeoverTransactionWithNcacTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:ScheduleOfListingExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "pbm:ReverseTakeoverTransactionWithNcacTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalentsTables", "longName": "996004 - Disclosure - Cash, Restricted Cash and Cash Equivalents (Tables)", "shortName": "Cash, Restricted Cash and Cash Equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.psyencebiomed.com/role/DigitalAssetsTables", "longName": "996005 - Disclosure - Digital Assets (Tables)", "shortName": "Digital Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfDigitalAssetHoldingsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "pbm:DisclosureOfDigitalAssets", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfDigitalAssetHoldingsExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "pbm:DisclosureOfDigitalAssets", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.psyencebiomed.com/role/LoanReceivableTables", "longName": "996006 - Disclosure - Loan Receivable (Tables)", "shortName": "Loan Receivable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfLoanProceeds", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "pbm:LoanReceivableTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfLoanProceeds", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "pbm:LoanReceivableTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.psyencebiomed.com/role/PrepaidExpensesTables", "longName": "996007 - Disclosure - Prepaid Expenses (Tables)", "shortName": "Prepaid Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.psyencebiomed.com/role/EquipmentTables", "longName": "996008 - Disclosure - Equipment (Tables)", "shortName": "Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateTables", "longName": "996009 - Disclosure - Psyence Labs Ltd. Investment and Investment in Associate (Tables)", "shortName": "Psyence Labs Ltd. Investment and Investment in Associate (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c0", "name": "pbm:ScheduleOfCarryingAmountOfInvestmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:ScheduleOfCarryingAmountOfInvestmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.psyencebiomed.com/role/AccountsPayableandAccruedLiabilitiesTables", "longName": "996010 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables", "longName": "996011 - Disclosure - Derivative Warrant Liabilities (Tables)", "shortName": "Derivative Warrant Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfPrivateWarrantExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfPrivateWarrantExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.psyencebiomed.com/role/ShareCapitalTables", "longName": "996012 - Disclosure - Share Capital (Tables)", "shortName": "Share Capital (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c0", "name": "pbm:ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityTables", "longName": "996013 - Disclosure - Convertible Note Liability (Tables)", "shortName": "Convertible Note Liability (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsTables", "longName": "996014 - Disclosure - PIPE Financing - Private Placement and Warrants (Tables)", "shortName": "PIPE Financing - Private Placement and Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfCommonSharesWarrantsInputsUsedInFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfCommonSharesWarrantsInputsUsedInFairValueMeasurementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.psyencebiomed.com/role/CapitalManagementTables", "longName": "996015 - Disclosure - Capital Management (Tables)", "shortName": "Capital Management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfTotalManagedCapitalTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DisclosureOfTotalManagedCapitalTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.psyencebiomed.com/role/TransactionswithRelatedPartiesTables", "longName": "996016 - Disclosure - Transactions with Related Parties (Tables)", "shortName": "Transactions with Related Parties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.psyencebiomed.com/role/IncomeTaxNoteTables", "longName": "996017 - Disclosure - Income Tax Note (Tables)", "shortName": "Income Tax Note (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c0", "name": "pbm:ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementTables", "longName": "996018 - Disclosure - Financial Instruments and Financial Risk Management (Tables)", "shortName": "Financial Instruments and Financial Risk Management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable", "longName": "996019 - Disclosure - Basis of Presentation - Schedule of Subsidiaries (Details)", "shortName": "Basis of Presentation - Schedule of Subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c48", "name": "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c48", "name": "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.psyencebiomed.com/role/MaterialAccountingPoliciesDetails", "longName": "996020 - Disclosure - Material Accounting Policies (Details)", "shortName": "Material Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c24", "name": "ifrs-full:ClosingForeignExchangeRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c24", "name": "ifrs-full:ClosingForeignExchangeRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable", "longName": "996021 - Disclosure - Material Accounting Policies - Schedule of Classification and Measurements of Financial Assets and Liabilities (Details)", "shortName": "Material Accounting Policies - Schedule of Classification and Measurements of Financial Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c51", "name": "pbm:ClassificationOfFinancialAssetsAndLiabilities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "pbm:ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c51", "name": "pbm:ClassificationOfFinancialAssetsAndLiabilities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "pbm:ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable", "longName": "996022 - Disclosure - Material Accounting Policies - \u200bSchedule of Change in Presentation Currency (Details)", "shortName": "Material Accounting Policies - \u200bSchedule of Change in Presentation Currency (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c13", "name": "ifrs-full:EquityAttributableToOwnersOfParent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c13", "name": "ifrs-full:EquityAttributableToOwnersOfParent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.psyencebiomed.com/role/CriticalAccountingEstimatesandJudgementsDetails", "longName": "996023 - Disclosure - Critical Accounting Estimates and Judgements (Details)", "shortName": "Critical Accounting Estimates and Judgements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c60", "name": "pbm:TradingPricePerShares", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c60", "name": "pbm:TradingPricePerShares", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails", "longName": "996024 - Disclosure - Reverse Takeover Transaction with NCAC (Details)", "shortName": "Reverse Takeover Transaction with NCAC (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c61", "name": "ifrs-full:ParValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "pbm:ReverseTakeoverTransactionWithNcacTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c61", "name": "ifrs-full:ParValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "pbm:ReverseTakeoverTransactionWithNcacTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable", "longName": "996025 - Disclosure - Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details)", "shortName": "Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c64", "name": "pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfListingExpensesTableTextBlock", "pbm:ReverseTakeoverTransactionWithNcacTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c64", "name": "pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfListingExpensesTableTextBlock", "pbm:ReverseTakeoverTransactionWithNcacTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalentsDetails", "longName": "996026 - Disclosure - Cash, Restricted Cash and Cash Equivalents (Details)", "shortName": "Cash, Restricted Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed", "unitRef": "cad", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed", "unitRef": "cad", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable", "longName": "996027 - Disclosure - Cash, Restricted Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "shortName": "Cash, Restricted Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:BalancesWithBanks", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:BalancesWithBanks", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.psyencebiomed.com/role/DigitalAssetsDetails", "longName": "996028 - Disclosure - Digital Assets (Details)", "shortName": "Digital Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c0", "name": "pbm:DigitalAssetDeposits", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "pbm:DisclosureOfDigitalAssets", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:DigitalAssetDeposits", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "pbm:DisclosureOfDigitalAssets", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable", "longName": "996029 - Disclosure - Digital Assets - Schedule of Digital Asset Holdings (Details)", "shortName": "Digital Assets - Schedule of Digital Asset Holdings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c0", "name": "pbm:FairValueOfDigitalAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfDigitalAssetHoldingsExplanatoryTextBlock", "pbm:DisclosureOfDigitalAssets", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:FairValueOfDigitalAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfDigitalAssetHoldingsExplanatoryTextBlock", "pbm:DisclosureOfDigitalAssets", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.psyencebiomed.com/role/LoanReceivableDetails", "longName": "996030 - Disclosure - Loan Receivable (Details)", "shortName": "Loan Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c78", "name": "ifrs-full:LoansAndAdvances", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "pbm:LoanReceivableTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c78", "name": "ifrs-full:LoansAndAdvances", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "pbm:LoanReceivableTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.psyencebiomed.com/role/ScheduleofLoanProceedsTable", "longName": "996031 - Disclosure - Loan Receivable - Schedule of Loan Proceeds (Details)", "shortName": "Loan Receivable - Schedule of Loan Proceeds (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:ShorttermBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "pbm:LoanReceivableTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:ShorttermBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "pbm:LoanReceivableTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.psyencebiomed.com/role/ScheduleofPrepaidExpensesTable", "longName": "996032 - Disclosure - Prepaid Expenses - Schedule of Prepaid Expenses (Details)", "shortName": "Prepaid Expenses - Schedule of Prepaid Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable", "longName": "996033 - Disclosure - Equipment - Schedule of Equipment (Details)", "shortName": "Equipment - Schedule of Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c89", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true }, "uniqueAnchor": { "contextRef": "c79", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "unique": true } }, "R67": { "role": "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails", "longName": "996034 - Disclosure - Psyence Labs Ltd. Investment and Investment in Associate (Details)", "shortName": "Psyence Labs Ltd. Investment and Investment in Associate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c5", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true }, "uniqueAnchor": { "contextRef": "c92", "name": "pbm:ConsiderationOfShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "pbm:DisclosureOfPsyenceLabsLtdInvestmentAndInvestmentInAssociate", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "unique": true } }, "R68": { "role": "http://www.psyencebiomed.com/role/ScheduleofCarryingAmountofInvestmentTable", "longName": "996035 - Disclosure - Psyence Labs Ltd. Investment and Investment in Associate - Schedule of Carrying Amount of Investment (Details)", "shortName": "Psyence Labs Ltd. Investment and Investment in Associate - Schedule of Carrying Amount of Investment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c0", "name": "pbm:PreviouslyHeldInterestRemeasuredToFairValueAtAcquisitionDateShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfCarryingAmountOfInvestmentTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "pbm:PreviouslyHeldInterestRemeasuredToFairValueAtAcquisitionDateShares", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfCarryingAmountOfInvestmentTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable", "longName": "996036 - Disclosure - Accounts Payable and Accrued Liabilities - \u200bSchedule of Accounts Payable and Accrued Liabilities (Details)", "shortName": "Accounts Payable and Accrued Liabilities - \u200bSchedule of Accounts Payable and Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "longName": "996037 - Disclosure - Derivative Warrant Liabilities (Details)", "shortName": "Derivative Warrant Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:ParValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true }, "uniqueAnchor": { "contextRef": "c6", "name": "pbm:CancellationOfPublicWarrants", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "unique": true } }, "R71": { "role": "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable", "longName": "996038 - Disclosure - Derivative Warrant Liabilities - Schedule of Private Warrants (Details)", "shortName": "Derivative Warrant Liabilities - Schedule of Private Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c118", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c118", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable", "longName": "996039 - Disclosure - Derivative Warrant Liabilities - Schedule of Derivative Warrant Liability (Details)", "shortName": "Derivative Warrant Liabilities - Schedule of Derivative Warrant Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c132", "name": "pbm:NumberOfShareIssuedWarrantLiability", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c132", "name": "pbm:NumberOfShareIssuedWarrantLiability", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable", "longName": "996040 - Disclosure - Derivative Warrant Liabilities - Schedule of Warrant Transactions (Details)", "shortName": "Derivative Warrant Liabilities - Schedule of Warrant Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c134", "name": "pbm:NumberOfWarrantsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfWarrantsExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c134", "name": "pbm:NumberOfWarrantsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfWarrantsExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable", "longName": "996041 - Disclosure - Derivative Warrant Liabilities - Schedule of Warrants Outstanding and Exercisable (Details)", "shortName": "Derivative Warrant Liabilities - Schedule of Warrants Outstanding and Exercisable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c137", "name": "pbm:WarrantsOrRightsExpirationDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfWarrantsOutstandingAndExercisableExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c137", "name": "pbm:WarrantsOrRightsExpirationDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfWarrantsOutstandingAndExercisableExplanatoryTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.psyencebiomed.com/role/ShareCapitalDetails", "longName": "996042 - Disclosure - Share Capital (Details)", "shortName": "Share Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c141", "name": "pbm:StockIssuedDuringPeriodShareStockSplits", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c141", "name": "pbm:StockIssuedDuringPeriodShareStockSplits", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable", "longName": "996043 - Disclosure - Share Capital - Schedule of Issued and Outstanding Common Shares (Details)", "shortName": "Share Capital - Schedule of Issued and Outstanding Common Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c171", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true }, "uniqueAnchor": { "contextRef": "c167", "name": "ifrs-full:IssuedCapital", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "unique": true } }, "R77": { "role": "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable", "longName": "996044 - Disclosure - Share Capital - Schedule of Issued and Outstanding Warrants (Details)", "shortName": "Share Capital - Schedule of Issued and Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c4", "name": "pbm:NumberOfSharesWarrantsIssuedForConvertibleNoteAddendum", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfIssuedAndOutstandingWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "pbm:NumberOfSharesWarrantsIssuedForConvertibleNoteAddendum", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfIssuedAndOutstandingWarrantsTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable", "longName": "996045 - Disclosure - Share Capital - Schedule of Warrants were Outstanding and Exercisable (Details)", "shortName": "Share Capital - Schedule of Warrants were Outstanding and Exercisable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c174", "name": "pbm:WarrantsExpiryDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfWarrantsWereOutstandingAndExercisableTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c174", "name": "pbm:WarrantsExpiryDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfWarrantsWereOutstandingAndExercisableTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.psyencebiomed.com/role/ScheduleofRestrictedStockUnitsTable", "longName": "996046 - Disclosure - Share Capital - Schedule of Restricted Stock Units (Details)", "shortName": "Share Capital - Schedule of Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c179", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfRestrictedStockUnitsRSUsTableTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c179", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfRestrictedStockUnitsRSUsTableTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.psyencebiomed.com/role/OtherIncomeDetails", "longName": "996047 - Disclosure - Other Income (Details)", "shortName": "Other Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c181", "name": "ifrs-full:OtherIncome", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c181", "name": "ifrs-full:OtherIncome", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.psyencebiomed.com/role/OtherExpenseDetails", "longName": "996048 - Disclosure - Other Expense (Details)", "shortName": "Other Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:OtherExpenseByNature", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:OtherExpenseByNature", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "longName": "996049 - Disclosure - Convertible Note Liability (Details)", "shortName": "Convertible Note Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:BorrowingsInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "td", "tr", "table", "ix:continuation", "pbm:LoanReceivableTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true }, "uniqueAnchor": { "contextRef": "c5", "name": "pbm:ConvertibleNoteFairValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "unique": true } }, "R83": { "role": "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable", "longName": "996050 - Disclosure - Convertible Note Liability - Schedule of Using the Black-Scholes Pricing Model (Details)", "shortName": "Convertible Note Liability - Schedule of Using the Black-Scholes Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c212", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c212", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "ix:continuation", "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.psyencebiomed.com/role/PromissoryNotesDetails", "longName": "996051 - Disclosure - Promissory Notes (Details)", "shortName": "Promissory Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c224", "name": "ifrs-full:RepaymentsOfCurrentBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "pbm:PromissoryNotesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c224", "name": "ifrs-full:RepaymentsOfCurrentBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "pbm:PromissoryNotesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.psyencebiomed.com/role/ELOCDetails", "longName": "996052 - Disclosure - ELOC (Details)", "shortName": "ELOC (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c240", "name": "pbm:EquityLineOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "pbm:EquityLineOfCreditDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c240", "name": "pbm:EquityLineOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "pbm:EquityLineOfCreditDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails", "longName": "996053 - Disclosure - PIPE Financing - Private Placement and Warrants (Details)", "shortName": "PIPE Financing - Private Placement and Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c250", "name": "pbm:NumberOfWarrantPurchased", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c250", "name": "pbm:NumberOfWarrantPurchased", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfPrivatePlacementAndWarrantsExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable", "longName": "996054 - Disclosure - PIPE Financing - Private Placement and Warrants - Schedule of Fair Value Allocation (Details)", "shortName": "PIPE Financing - Private Placement and Warrants - Schedule of Fair Value Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c257", "name": "ifrs-full:IssuedCapitalOrdinaryShares", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c257", "name": "ifrs-full:IssuedCapitalOrdinaryShares", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable", "longName": "996055 - Disclosure - PIPE Financing - Private Placement and Warrants - Schedule of Pre-funded Warrants (Details)", "shortName": "PIPE Financing - Private Placement and Warrants - Schedule of Pre-funded Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c258", "name": "ifrs-full:SignificantUnobservableInputEntitysOwnEquityInstruments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfPrefundedWarrantsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c258", "name": "ifrs-full:SignificantUnobservableInputEntitysOwnEquityInstruments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfPrefundedWarrantsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable", "longName": "996056 - Disclosure - Capital Management - Schedule of Total Managed Capital (Details)", "shortName": "Capital Management - Schedule of Total Managed Capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:IssuedCapital", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:CurrentFinancialLiabilitiesAtAmortisedCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:DisclosureOfTotalManagedCapitalTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "unique": true } }, "R90": { "role": "http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable", "longName": "996057 - Disclosure - Transactions with Related Parties - Schedule of Key Management Personnel (Details)", "shortName": "Transactions with Related Parties - Schedule of Key Management Personnel (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.psyencebiomed.com/role/IncomeTaxNoteDetails", "longName": "996058 - Disclosure - Income Tax Note (Details)", "shortName": "Income Tax Note (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c279", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "pbm:ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c279", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "pbm:ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable", "longName": "996059 - Disclosure - Income Tax Note - Schedule of Canadian Federal and Provincial Statutory Income Tax Rate (Details)", "shortName": "Income Tax Note - Schedule of Canadian Federal and Provincial Statutory Income Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c0", "name": "ifrs-full:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ifrs-full:TaxExpenseIncomeAtApplicableTaxRate", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "unique": true } }, "R93": { "role": "http://www.psyencebiomed.com/role/ScheduleofComponentsofDeferredTaxTable", "longName": "996060 - Disclosure - Income Tax Note - Schedule of Components of Deferred Tax (Details)", "shortName": "Income Tax Note - Schedule of Components of Deferred Tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable", "longName": "996061 - Disclosure - Income Tax Note - Schedule of Unrecognized Deferred Tax Assets (Details)", "shortName": "Income Tax Note - Schedule of Unrecognized Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ix:continuation", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable", "longName": "996062 - Disclosure - Income Tax Note - Schedule of Non-Capital Loss Carry Forwards (Details)", "shortName": "Income Tax Note - Schedule of Non-Capital Loss Carry Forwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c301", "name": "pbm:NonCapitalLossCarryForwards", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:SummaryOfOperatingLossCarryForwardsTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c301", "name": "pbm:NonCapitalLossCarryForwards", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "pbm:SummaryOfOperatingLossCarryForwardsTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementDetails", "longName": "996063 - Disclosure - Financial Instruments and Financial Risk Management (Details)", "shortName": "Financial Instruments and Financial Risk Management (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c4", "name": "pbm:PercentageOfReasonablyPossibleChangeInRiskAssumption", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "pbm:PercentageOfReasonablyPossibleChangeInRiskAssumption", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R97": { "role": "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable", "longName": "996064 - Disclosure - Financial Instruments and Financial Risk Management - Schedule of Carrying Value of the Financial Instruments (Details)", "shortName": "Financial Instruments and Financial Risk Management - Schedule of Carrying Value of the Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R98": { "role": "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable", "longName": "996065 - Disclosure - Financial Instruments and Financial Risk Management - Schedule of Maturity of the Contractual Obligations (Details)", "shortName": "Financial Instruments and Financial Risk Management - Schedule of Maturity of the Contractual Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:FinancialLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c4", "name": "ifrs-full:FinancialLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.psyencebiomed.com/role/SubsequentEventsDetails", "longName": "996066 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c4", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "first": true }, "uniqueAnchor": { "contextRef": "c328", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0294983-20f_psyence.htm", "unique": true } } }, "tag": { "country_AU": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "AU", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable", "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Australia [Member]", "label": "AUSTRALIA" } } }, "auth_ref": [] }, "pbm_AccountingMethodOfSubsidiary": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AccountingMethodOfSubsidiary", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting method", "documentation": "The accounting methods used in subsidiaries are classified as consolidated or unconsolidated.", "label": "Accounting Method Of Subsidiary" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "pbm_AccountsPayableAndAccruedLiabilitieMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AccountsPayableAndAccruedLiabilitieMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities [Member]", "label": "Accounts Payable And Accrued Liabilitie Member" } } }, "auth_ref": [] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "parentTag": "pbm_CurrentAccountsPayableAndAccruedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Accruals classified as current" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r339" ] }, "pbm_AccumulatedDepreciationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AccumulatedDepreciationAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Depreciation", "label": "Accumulated Depreciation Abstract" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Depreciation [Member]", "label": "Accumulated depreciation and amortisation [member]" } } }, "auth_ref": [ "r15", "r318", "r320", "r321", "r322" ] }, "ifrs-full_AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AcquisitiondateFairValueOfEquityInterestInAcquireeHeldByAcquirerImmediatelyBeforeAcquisitionDate", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingAmountofInvestmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Previously held interest \u2013 remeasured to fair value at Acquisition Date, Amount", "label": "Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date" } }, "en": { "role": { "documentation": "The acquisition-date fair value of equity interest in the acquiree held by the acquirer immediately before the acquisition date in a business combination achieved in stages. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r111" ] }, "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails", "http://www.psyencebiomed.com/role/ScheduleofCarryingAmountofInvestmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred for additional shares acquired, Amount", "verboseLabel": "Total consideration", "label": "Consideration transferred, acquisition-date fair value" } }, "en": { "role": { "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r110", "r202" ] }, "pbm_AcquisitionsSharesHeld": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AcquisitionsSharesHeld", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions shares held (in Shares)", "documentation": "Represents the acquisitions shares held.", "label": "Acquisitions Shares Held" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions other than through business combinations, property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r10", "r168" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of outstanding shares - diluted (in Shares)", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r41" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInLoansAndAdvancesToBanks": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInLoansAndAdvancesToBanks", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Loan receivable", "label": "Adjustments for decrease (increase) in loans and advances to banks" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in loans and advances to banks to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Loans and advances to banks; Profit (loss)]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Adjustments for decrease (increase) in other operating receivables" } } }, "auth_ref": [ "r325" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaids", "label": "Adjustments for decrease (increase) in prepaid expenses" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_AdjustmentsForDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationExpense", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Adjustments for depreciation expense" } }, "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r327" ] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value loss on Digital Assets", "label": "Adjustments for fair value losses (gains)" } } }, "auth_ref": [ "r326" ] }, "pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "documentation": "Adjustments for increase (decrease) in accounts payable and accrued liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Increase Decrease In Accounts Payable And Accrued Liabilities" } } }, "auth_ref": [] }, "pbm_AdjustmentsForListingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AdjustmentsForListingExpense", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow", "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Listing expense", "documentation": "Adjustments for listing expense to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Listing Expense" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash adjustment:", "label": "Adjustments to reconcile operating profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Adjustments for share-based payments" } } }, "auth_ref": [ "r326" ] }, "pbm_AdjustmentsForTransactionExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AdjustmentsForTransactionExpenses", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction expenses", "documentation": "Adjustments for transaction expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Transaction Expenses" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange", "label": "Adjustments for unrealised foreign exchange losses (gains)" } } }, "auth_ref": [ "r257", "r326" ] }, "pbm_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AgreementAxis", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement [Axis]", "label": "Agreement Axis" } } }, "auth_ref": [] }, "pbm_AgreementDomainDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AgreementDomainDomain", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "AgreementDomain [Domain]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesCommitmentSharesELOC": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesCommitmentSharesELOC", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Commitment shares ELOC (in Dollars)", "documentation": "Amount of Common shares, Commitment shares ELOC.", "label": "Amount Of Common Shares Commitment Shares ELOC" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesExerciseOfRSUs": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesExerciseOfRSUs", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Exercise of RSUs (in Dollars)", "documentation": "Amount of common shares, exercise of RSUs.", "label": "Amount Of Common Shares Exercise Of RSUs" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesShareIssuanceCostsForELOC": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesShareIssuanceCostsForELOC", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Share issuance costs for ELOC (in Dollars)", "documentation": "Amount of Common shares, Share issuance costs for ELOC.", "label": "Amount Of Common Shares Share Issuance Costs For ELOC" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesShareIssuanceCostsForPIPEFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesShareIssuanceCostsForPIPEFinancing", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Share issuance costs for PIPE financing (in Dollars)", "documentation": "Amount of Common shares, Share issuance costs for PIPE financing.", "label": "Amount Of Common Shares Share Issuance Costs For PIPEFinancing" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesShareIssuanceForAssociate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesShareIssuanceForAssociate", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Share issuance for Associate (in Dollars)", "documentation": "Amount of common shares, share issuance for associate.", "label": "Amount Of Common Shares Share Issuance For Associate" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesShareIssuanceToNCACShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesShareIssuanceToNCACShareholders", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Share issuance to NCAC shareholders (in Dollars)", "documentation": "Amount of common shares, share issuance to NCAC shareholders.", "label": "Amount Of Common Shares Share Issuance To NCACShareholders" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesShareIssuanceToPGI": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesShareIssuanceToPGI", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Share issuance to PGI (in Dollars)", "documentation": "Amount of common shares, share issuance to PGI.", "label": "Amount Of Common Shares Share Issuance To PGI" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesSharesIssuanceCostsForPIPEPrefundedWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesSharesIssuanceCostsForPIPEPrefundedWarrantsExercised", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Shares issuance costs for PIPE pre-funded warrants exercised (in Dollars)", "documentation": "Amount of Common shares, Shares issuance costs for PIPE pre-funded warrants exercised.", "label": "Amount Of Common Shares Shares Issuance Costs For PIPEPrefunded Warrants Exercised" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesSharesIssuedForDebtSettlementinDollars": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesSharesIssuedForDebtSettlementinDollars", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Shares issued for debt settlement (in Dollars)", "documentation": "Amount of common shares, shares issued for debt settlement.", "label": "Amount Of Common Shares Shares Issued For Debt Settlementin Dollars" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesSharesIssuedForELOC": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesSharesIssuedForELOC", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Shares issued for ELOC (in Dollars)", "documentation": "Amount of common shares, shares issued for ELOC.", "label": "Amount Of Common Shares Shares Issued For ELOC" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesSharesIssuedForPIPEFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesSharesIssuedForPIPEFinancing", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Shares issued for PIPE financing (in Dollars)", "documentation": "Amount of Common shares, Shares issued for PIPE financing.", "label": "Amount Of Common Shares Shares Issued For PIPEFinancing" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesSharesIssuedForPIPEPrefundedWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesSharesIssuedForPIPEPrefundedWarrantsExercised", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Shares issued for PIPE pre-funded warrants exercised (in Dollars)", "documentation": "Amount of Common shares, Shares issued for PIPE pre-funded warrants exercised.", "label": "Amount Of Common Shares Shares Issued For PIPEPrefunded Warrants Exercised" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesSharesIssuedForPsyLabsShareExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesSharesIssuedForPsyLabsShareExchange", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Shares issued for PsyLabs share exchange (in Dollars)", "documentation": "Amount of Common shares, Shares issued for PsyLabs share exchange.", "label": "Amount Of Common Shares Shares Issued For Psy Labs Share Exchange" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesSharesIssuedOnConversionOfConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesSharesIssuedOnConversionOfConvertibleNote", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Shares issued on conversion of convertible note (in Dollars)", "documentation": "Amount of common shares, shares issued on conversion of convertible note.", "label": "Amount Of Common Shares Shares Issued On Conversion Of Convertible Note" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesSharesIssuedOnConversionOfConvertibleNoteWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesSharesIssuedOnConversionOfConvertibleNoteWarrants", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Shares issued on conversion of convertible note warrants (in Dollars)", "documentation": "Amount of Common shares, Shares issued on conversion of convertible note warrants.", "label": "Amount Of Common Shares Shares Issued On Conversion Of Convertible Note Warrants" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesSharesIssuedOnConversionOfNCACPromissoryNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesSharesIssuedOnConversionOfNCACPromissoryNotes", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Shares issued on conversion of NCAC promissory notes (in Dollars)", "documentation": "Amount of Common shares, Shares issued on conversion of NCAC promissory notes.", "label": "Amount Of Common Shares Shares Issued On Conversion Of NCACPromissory Notes" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesSharesIssuedOnConversionOfPGIPromissoryNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesSharesIssuedOnConversionOfPGIPromissoryNotes", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Shares issued on conversion of PGI promissory notes (in Dollars)", "documentation": "Amount of Common shares, Shares issued on conversion of PGI promissory notes.", "label": "Amount Of Common Shares Shares Issued On Conversion Of PGIPromissory Notes" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesSharesIssuedToThirdPartyAdvisors": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesSharesIssuedToThirdPartyAdvisors", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Shares issued to third party advisors (in Dollars)", "documentation": "Amount of common shares, shares issued to third party advisors.", "label": "Amount Of Common Shares Shares Issued To Third Party Advisors" } } }, "auth_ref": [] }, "pbm_AmountOfCommonSharesWarrantExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfCommonSharesWarrantExchange", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Common shares, Warrant exchange (in Dollars)", "documentation": "Amount of Common shares, Warrant exchange.", "label": "Amount Of Common Shares Warrant Exchange" } } }, "auth_ref": [] }, "pbm_AmountOfConvertibleNoteTerminationAgreementWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfConvertibleNoteTerminationAgreementWarrantsExercised", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Warrants, Convertible note Termination Agreement warrants exercised (in Dollars)", "documentation": "Amount of convertible note termination agreement warrants exercised.", "label": "Amount Of Convertible Note Termination Agreement Warrants Exercised" } } }, "auth_ref": [] }, "pbm_AmountOfIssuanceCostsForPIPEFinancingWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfIssuanceCostsForPIPEFinancingWarrants", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Warrants, Issuance costs for PIPE financing warrants (in Dollars)", "documentation": "Amount of issuance costs for PIPE financing warrants.", "label": "Amount Of Issuance Costs For PIPEFinancing Warrants" } } }, "auth_ref": [] }, "pbm_AmountOfIssuanceCostsForPIPEPrefundedWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfIssuanceCostsForPIPEPrefundedWarrantsExercised", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Warrants, Issuance costs for PIPE pre-funded warrants exercised (in Dollars)", "documentation": "Amount of issuance costs for PIPE pre-funded warrants exercised.", "label": "Amount Of Issuance Costs For PIPEPrefunded Warrants Exercised" } } }, "auth_ref": [] }, "pbm_AmountOfPIPEFinancingWarrantIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfPIPEFinancingWarrantIssuance", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Warrants, PIPE financing warrant issuance (in Dollars)", "documentation": "Amount of PIPE financing warrant issuance.", "label": "Amount Of PIPEFinancing Warrant Issuance" } } }, "auth_ref": [] }, "pbm_AmountOfPIPEFinancingWarrantIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfPIPEFinancingWarrantIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Warrants, PIPE financing warrant issuance costs (in Dollars)", "documentation": "Amount of PIPE financing warrant issuance costs.", "label": "Amount Of PIPEFinancing Warrant Issuance Costs" } } }, "auth_ref": [] }, "pbm_AmountOfPIPEPrefundedWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfPIPEPrefundedWarrantsExercised", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Warrants, PIPE pre-funded warrants exercised (in Dollars)", "documentation": "Amount of PIPE pre-funded warrants exercised.", "label": "Amount Of PIPEPrefunded Warrants Exercised" } } }, "auth_ref": [] }, "pbm_AmountOfWarrantsEndingBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfWarrantsEndingBalance", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Amount of Warrants, Ending Balance (in Dollars)", "documentation": "Amount of warrants ending balance.", "label": "Amount Of Warrants Ending Balance" } } }, "auth_ref": [] }, "pbm_AmountOfWarrantsIssuedForConvertibleNoteAddendum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfWarrantsIssuedForConvertibleNoteAddendum", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Warrants, Warrants issued for convertible note Addendum (in Dollars)", "documentation": "Amount of warrants issued for convertible note addendum.", "label": "Amount Of Warrants Issued For Convertible Note Addendum" } } }, "auth_ref": [] }, "pbm_AmountOfWarrantsOpeningBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AmountOfWarrantsOpeningBalance", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Amount of Warrants, Opening balance (in Dollars)", "documentation": "Amount of warrants opening balance.", "label": "Amount Of Warrants Opening Balance" } } }, "auth_ref": [] }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmountsPayableRelatedPartyTransactions", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable (in Dollars)", "label": "Amounts payable, related party transactions" } }, "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r24", "r27", "r176" ] }, "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AnalysisOfIncomeAndExpenseAbstract", "lang": { "en-us": { "role": { "label": "Other Expense [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.psyencebiomed.com/role/IncomeTaxNoteDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of statutory income tax rate", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r4", "r163" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r81", "r82", "r84", "r132", "r134", "r213", "r214", "r235" ] }, "ifrs-full_AtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AtFairValueMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Allocation [Member]", "label": "At fair value [member]" } }, "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } } }, "auth_ref": [ "r48", "r52", "r73", "r81", "r188", "r212", "r213" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r289", "r290", "r299" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r289", "r290", "r299" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r289", "r290", "r299" ] }, "dei_AuditorOpinionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorOpinionTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Opinion [Text Block]", "label": "Auditor Opinion [Text Block]" } } }, "auth_ref": [ "r313" ] }, "pbm_AugustMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "AugustMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "August 20, 2024 [Member]", "label": "August Member" } } }, "auth_ref": [] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.psyencebiomed.com/role/MaterialAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average rate", "label": "Average foreign exchange rate" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r335" ] }, "ifrs-full_BalancesWithBanks": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BalancesWithBanks", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable": { "parentTag": "ifrs-full_RestrictedCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unrestricted cash held with chartered banks", "label": "Balances with banks" } }, "en": { "role": { "documentation": "The amount of cash balances held at banks." } } }, "auth_ref": [ "r328" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Income/(Loss) per share - basic (in Dollars per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r39", "r40" ] }, "pbm_BasisofPresentationScheduleofSubsidiariesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "BasisofPresentationScheduleofSubsidiariesDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation - Schedule of Subsidiaries (Details) [Table]" } } }, "auth_ref": [] }, "pbm_BitcoinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "BitcoinMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Bitcoin [Member]", "label": "Bitcoin Member" } } }, "auth_ref": [] }, "pbm_BorrowerAgreedToPurchaseShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "BorrowerAgreedToPurchaseShares", "presentation": [ "http://www.psyencebiomed.com/role/LoanReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrower agreed to purchase shares (in Shares)", "documentation": "Borrower agreed to purchase shares.", "label": "Borrower Agreed To Purchase Shares" } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable": { "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "NCAC promissory note (Note 18)", "label": "Borrowings" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r337" ] }, "ifrs-full_BorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsAbstract", "lang": { "en-us": { "role": { "label": "Convertible Note Liability [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r331" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/ScheduleofLoanProceedsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate (RBC Prime Rate + 1% per annum)", "verboseLabel": "Interest rate", "label": "Borrowings, interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_BorrowingsMaturity": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsMaturity", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofLoanProceedsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity date (3 month term)", "label": "Borrowings, maturity" } }, "en": { "role": { "documentation": "The maturity of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bottom of range [Member]", "verboseLabel": "Bottom of Range [Member]", "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r55", "r86", "r92", "r102", "r150", "r262", "r263", "r331" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r290", "r299" ] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "CA", "presentation": [ "http://www.psyencebiomed.com/role/IncomeTaxNoteDetails", "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable", "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Canada [Member]", "label": "CANADA" } } }, "auth_ref": [] }, "pbm_CancellationOfPublicWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "CancellationOfPublicWarrants", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancellation of public warrants", "documentation": "The number of public warrants.", "label": "Cancellation Of Public Warrants" } } }, "auth_ref": [] }, "pbm_CapitalManagementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "CapitalManagementDisclosureTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/CapitalManagement" ], "lang": { "en-us": { "role": { "terseLabel": "Capital management", "documentation": "The entire disclosure on capital management.", "label": "Capital Management Disclosure Text Block" } } }, "auth_ref": [] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Options Reserve", "label": "Capital reserve" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r337" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r9", "r12", "r45", "r46", "r49", "r50", "r51", "r52", "r53", "r112", "r118", "r119", "r167", "r170", "r182", "r183", "r185", "r186", "r187", "r188", "r189", "r203", "r208", "r209" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } } }, "auth_ref": [ "r12", "r46", "r49", "r51", "r52", "r112", "r118", "r119", "r170", "r183", "r185", "r187", "r188", "r203", "r208", "r209" ] }, "pbm_CarryingValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "CarryingValueAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "label": "Carrying Value Abstract" } } }, "auth_ref": [] }, "ifrs-full_CashAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAbstract", "lang": { "en-us": { "role": { "label": "Cash, Restricted Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "pbm_CashAndCashEquivalentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "CashAndCashEquivalentMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents [Member]", "label": "Cash And Cash Equivalent Member" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable": { "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "http://www.psyencebiomed.com/role/ConsolidatedCashFlow", "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of year", "periodEndLabel": "Cash and cash equivalents, end of year", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalent", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r56", "r76", "r151", "r230" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsHeldByEntityUnavailableForUseByGroup", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrepaidExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Funds held in trust with attorneys", "label": "Cash and cash equivalents held by entity unavailable for use by group" } }, "en": { "role": { "documentation": "The amount of significant cash and cash equivalent balances held by the entity that are not available for use by the group. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r58", "r153" ] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInRestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in restricted cash", "label": "Cash flows from (used in) decrease (increase) in restricted cash and cash equivalents" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Cash provided from financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r54", "r59" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Cash used for investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r54", "r59" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Cash used in operating activities", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r54", "r59" ] }, "ifrs-full_CashTransferred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashTransferred", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ELOCDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total consideration amount", "label": "Cash transferred" } }, "en": { "role": { "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r109", "r201" ] }, "pbm_CashUSDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "CashUSDMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cash (USD) [Member]", "label": "Cash USDMember" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "\u200bSchedule of Accounts Payable and Accrued Liabilities [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/OtherExpenseDetails", "http://www.psyencebiomed.com/role/PromissoryNotesDetails", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails", "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable", "http://www.psyencebiomed.com/role/ShareCapitalDetails", "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r26", "r178" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/OtherExpenseDetails", "http://www.psyencebiomed.com/role/PromissoryNotesDetails", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails", "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable", "http://www.psyencebiomed.com/role/ShareCapitalDetails", "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r26", "r178" ] }, "pbm_ChangesInOperatingAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ChangesInOperatingAssetsAndLiabilitiesAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in working capital:", "label": "Changes In Operating Assets And Liabilities Abstract" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "pbm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails", "http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price (in Dollars per share)", "verboseLabel": "Common shares estimated share price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.psyencebiomed.com/role/ELOCDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r94", "r124", "r125", "r138", "r139", "r221" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/OtherIncomeDetails", "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails", "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable", "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable", "http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r118", "r120", "r121", "r122", "r208", "r210" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r118", "r120", "r121", "r122", "r208", "r210" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable", "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r124", "r125", "r138", "r139" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable", "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r124", "r125", "r138", "r139" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r13", "r171" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/DocumentAndEntityInformation", "http://www.psyencebiomed.com/role/ELOCDetails", "http://www.psyencebiomed.com/role/OtherExpenseDetails", "http://www.psyencebiomed.com/role/PromissoryNotesDetails", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails", "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r149", "r218", "r244" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/DocumentAndEntityInformation", "http://www.psyencebiomed.com/role/ELOCDetails", "http://www.psyencebiomed.com/role/OtherExpenseDetails", "http://www.psyencebiomed.com/role/PromissoryNotesDetails", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails", "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r149", "r218", "r244" ] }, "pbm_ClassificationOfFinancialAssetsAndLiabilities": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ClassificationOfFinancialAssetsAndLiabilities", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Classification", "documentation": "Classification of financial assets and liabilities.", "label": "Classification Of Financial Assets And Liabilities" } } }, "auth_ref": [] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.psyencebiomed.com/role/MaterialAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Closing rate", "label": "Closing foreign exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r335" ] }, "pbm_CommonSharesWithoutParValueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "CommonSharesWithoutParValueMember", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares, without par value", "label": "Common Shares Without Par Value Member" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable", "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r225" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r225" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL COMPREHENSIVE INCOME/(LOSS)", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r66", "r69", "r75", "r180", "r191", "r222", "r246", "r259" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable", "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment [Member]", "verboseLabel": "Equipment [Member]", "label": "Computer equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r317" ] }, "pbm_ConsiderationOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ConsiderationOfShares", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration of shares (in Shares)", "documentation": "Represent the consideration of shares.", "label": "Consideration Of Shares" } } }, "auth_ref": [] }, "pbm_ConsiderationPaidAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ConsiderationPaidAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration paid:", "label": "Consideration Paid Abstract" } } }, "auth_ref": [] }, "pbm_ConsiderationTransferredForAdditionalSharesAcquiredShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ConsiderationTransferredForAdditionalSharesAcquiredShares", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingAmountofInvestmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred for additional shares acquired, Shares (in Shares)", "documentation": "The number of consideration transferred for additional shares acquired, shares.", "label": "Consideration Transferred For Additional Shares Acquired Shares" } } }, "auth_ref": [] }, "pbm_ConsiderationTransferredForAdditionalSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ConsiderationTransferredForAdditionalSharesMember", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration Transferred for Additional Shares [Member]", "label": "Consideration Transferred For Additional Shares Member" } } }, "auth_ref": [] }, "pbm_ConsolidatedStatementsOfChangesInShareholdersEquityDeficitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ConsolidatedStatementsOfChangesInShareholdersEquityDeficitAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements Of Changes In Shareholders Equity Deficit Abstract" } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Name", "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_ConvertibleInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ConvertibleInstrumentsMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Instruments [Member]", "label": "Convertible instruments [member]" } }, "en": { "role": { "documentation": "This member stands for convertible instruments." } } }, "auth_ref": [ "r319" ] }, "pbm_ConvertibleNoteFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ConvertibleNoteFairValue", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible note, fair value", "documentation": "Represents the fair value of convertible note.", "label": "Convertible Note Fair Value" } } }, "auth_ref": [] }, "pbm_ConvertibleNoteLiabilityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ConvertibleNoteLiabilityDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Note Liability (Details) [Table]" } } }, "auth_ref": [] }, "pbm_ConvertibleNoteLiabilityScheduleofUsingtheBlackScholesPricingModelDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ConvertibleNoteLiabilityScheduleofUsingtheBlackScholesPricingModelDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "label": "Convertible Note Liability - Schedule of Using the Black-Scholes Pricing Model (Details) [Table]" } } }, "auth_ref": [] }, "pbm_CostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "CostAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Cost Abstract" } } }, "auth_ref": [] }, "pbm_CostOfDigitalAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "CostOfDigitalAsset", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "documentation": "Amount of digital asset.", "label": "Cost Of Digital Asset" } } }, "auth_ref": [] }, "ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CountryOfIncorporationOrResidenceOfSubsidiary", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Place of incorporation", "label": "Country of incorporation of subsidiary" } }, "en": { "role": { "documentation": "The country in which a subsidiary of the entity is incorporated. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r33", "r36", "r70", "r71" ] }, "ifrs-full_CreationDateAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CreationDateAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "label": "Creation date [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r60", "r61", "r64", "r155", "r156", "r159" ] }, "ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CumulativeEffectAtDateOfInitialApplicationAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable" ], "lang": { "en-us": { "role": { "label": "Cumulative effect at date of initial application [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r334" ] }, "pbm_CurrentAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "CurrentAccountsPayableAndAccruedLiabilities", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 }, "http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Accounts payable and accrued liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Current Accounts Payable And Accrued Liabilities" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r74", "r239", "r259" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Current assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative warrant liabilities", "label": "Current derivative financial liabilities" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r337" ] }, "ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentFinancialLiabilitiesAtAmortisedCost", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Current financial liabilities at amortised cost" } }, "en": { "role": { "documentation": "The amount of current financial liabilities measured at amortised cost. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r127", "r205" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Current liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "http://www.psyencebiomed.com/role/ScheduleofPrepaidExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expense", "verboseLabel": "Total", "label": "Current prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r335" ] }, "ifrs-full_CurrentPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepayments", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrepaidExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Current prepayments" } }, "en": { "role": { "documentation": "The amount of current prepayments. [Refer: Prepayments]" } } }, "auth_ref": [ "r276", "r281" ] }, "ifrs-full_CurrentPrepaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaymentsAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "parentTag": "pbm_CurrentAccountsPayableAndAccruedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Current provisions" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r232" ] }, "ifrs-full_CurrentRestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentRestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 }, "http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable": { "parentTag": "ifrs-full_RestrictedCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Current restricted cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } } }, "auth_ref": [ "r337" ] }, "ifrs-full_CurrentWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentWarrantLiability", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable": { "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable", "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Amount, Opening balance", "periodEndLabel": "Amount, Balance ending", "negatedLabel": "Derivative warrant liabilities (Note 13)", "label": "Current warrant liability" } }, "en": { "role": { "documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]" } } }, "auth_ref": [ "r337" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]", "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r297", "r310" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]", "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r297", "r310" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]", "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r298", "r311" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]", "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r293", "r306" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Management Processes Integrated [Flag]", "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r294", "r307" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Management Processes Integrated [Text Block]", "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r294", "r307" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r292", "r305" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r292", "r305" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r292", "r305" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Management Third Party Engaged [Flag]", "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r295", "r308" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]", "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r296", "r309" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]", "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r296", "r309" ] }, "pbm_DebtInstrumentConvertibleInitialConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DebtInstrumentConvertibleInitialConversionPrice", "presentation": [ "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price (in Dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument Convertible Initial Conversion Price" } } }, "auth_ref": [] }, "ifrs-full_DebtInstrumentsHeldMeasuredAtFairValueThroughOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DebtInstrumentsHeldMeasuredAtFairValueThroughOtherComprehensiveIncome", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of notes", "label": "Debt instruments held measured at fair value through other comprehensive income" } }, "en": { "role": { "documentation": "The amount of instruments representing indebtedness held by the entity that are measured at fair value through other comprehensive income. [Refer: Debt instruments held; Financial assets measured at fair value through other comprehensive income]" } } }, "auth_ref": [ "r337" ] }, "pbm_DecemberTwenteyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DecemberTwenteyFourMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "December 24, 2024 [Member]", "label": "December Twentey Four Member" } } }, "auth_ref": [] }, "pbm_DecemberTwentyFourOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DecemberTwentyFourOneMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "December 24, 2024 [Member]", "label": "December Twenty Four One Member" } } }, "auth_ref": [] }, "pbm_DecemberTwentyFourTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DecemberTwentyFourTwoMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "December 24, 2024 [Member]", "label": "December Twenty Four Two Member" } } }, "auth_ref": [] }, "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized deferred tax asset", "label": "Deductible temporary differences for which no deferred tax asset is recognised" } }, "en": { "role": { "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r5", "r164" ] }, "pbm_DeferredTaxAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DeferredTaxAssetAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofComponentsofDeferredTaxTable" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset", "label": "Deferred Tax Asset Abstract" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofComponentsofDeferredTaxTable": { "parentTag": "ifrs-full_DeferredTaxLiabilityAsset", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofComponentsofDeferredTaxTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-capital losses carried forward-Canada", "label": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r6", "r165", "r233", "r236" ] }, "ifrs-full_DeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssetsAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Components of Deferred Tax [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofComponentsofDeferredTaxTable": { "parentTag": "ifrs-full_DeferredTaxLiabilityAsset", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofComponentsofDeferredTaxTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment in Associate", "label": "Deferred tax liabilities" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r6", "r165", "r233", "r236" ] }, "pbm_DeferredTaxLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DeferredTaxLiabilityAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofComponentsofDeferredTaxTable" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Deferred Tax Liability Abstract" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxLiabilityAsset", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofComponentsofDeferredTaxTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofComponentsofDeferredTaxTable" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax asset and liability", "label": "Deferred tax liability (asset)" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r6", "r165" ] }, "ifrs-full_DepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationExpense", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Depreciation", "label": "Depreciation expense, operating" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipment", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Charge for the year", "label": "Depreciation, property, plant and equipment, operating" } } }, "auth_ref": [ "r11", "r14", "r169" ] }, "pbm_DerivativeWarrantLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DerivativeWarrantLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities [Abstract]" } } }, "auth_ref": [] }, "pbm_DerivativeWarrantLiabilitiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DerivativeWarrantLiabilitiesDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities (Details) [Table]" } } }, "auth_ref": [] }, "pbm_DerivativeWarrantLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DerivativeWarrantLiabilitiesLineItems", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities [Line Items]" } } }, "auth_ref": [] }, "pbm_DerivativeWarrantLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DerivativeWarrantLiabilitiesMember", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative warrant liability [Member]", "label": "Derivative Warrant Liabilities Member" } } }, "auth_ref": [] }, "pbm_DerivativeWarrantLiabilitiesScheduleofPrivateWarrantsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DerivativeWarrantLiabilitiesScheduleofPrivateWarrantsDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable" ], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities - Schedule of Private Warrants (Details) [Table]" } } }, "auth_ref": [] }, "pbm_DerivativeWarrantLiabilitiesScheduleofWarrantTransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DerivativeWarrantLiabilitiesScheduleofWarrantTransactionsDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable" ], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities - Schedule of Warrant Transactions (Details) [Table]" } } }, "auth_ref": [] }, "pbm_DerivativeWarrantLiabilitiesScheduleofWarrantsOutstandingandExercisableDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DerivativeWarrantLiabilitiesScheduleofWarrantsOutstandingandExercisableDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "label": "Derivative Warrant Liabilities - Schedule of Warrants Outstanding and Exercisable (Details) [Table]" } } }, "auth_ref": [] }, "pbm_DescriptionOfAccountingPolicyForDigitalAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DescriptionOfAccountingPolicyForDigitalAssetsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Digital Assets", "documentation": "The description of the entity's material accounting policy information for Digital Assets . [Refer: Classes of financial instruments [domain]]", "label": "Description Of Accounting Policy For Digital Assets Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Income/(loss) per share", "label": "Description of accounting policy for earnings per share [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for earnings per share." } } }, "auth_ref": [ "r336" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments", "label": "Description of accounting policy for financial instruments [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Description of accounting policy for foreign currency translation [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r336" ] }, "ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForGovernmentGrants", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Government grants", "label": "Description of accounting policy for government grants [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]" } } }, "auth_ref": [ "r18", "r172" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Description of accounting policy for income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r336" ] }, "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociates", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Associate", "label": "Description of accounting policy for investment in associates [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for investments in associates. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r336" ] }, "pbm_DescriptionOfAccountingPolicyForInvestmentInPsyLabstextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DescriptionOfAccountingPolicyForInvestmentInPsyLabstextBlock", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in PsyLabs", "documentation": "The description of the entity's material accounting policy information for investments in PsyLabs. [Refer: Total for all associates [member]]", "label": "Description Of Accounting Policy For Investment In Psy Labstext Block" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Description of accounting policy for provisions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Description of accounting policy for research and development expense [text block]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Description of accounting policy for restricted cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation", "label": "Description of accounting policy for share-based payment transactions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transactions", "label": "Description of accounting policy for transactions with related parties [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions with related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r336" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r57", "r152" ] }, "ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfNatureAndAmountOfChangeInAccountingEstimate", "presentation": [ "http://www.psyencebiomed.com/role/MaterialAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "\u200bSchedule of Change in Presentation Currency", "label": "Description of nature of change in accounting estimate [text block]" } }, "en": { "role": { "documentation": "The description of the nature of changes in accounting estimates that have effects in the current period or are expected to have effects in future periods." } } }, "auth_ref": [ "r63", "r158" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "label": "Risk free interest rate, share options granted" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r104" ] }, "ifrs-full_DescriptionOfVoluntaryChangeInAccountingPolicy": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfVoluntaryChangeInAccountingPolicy", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accounting policy", "label": "Disclosure of voluntary change in accounting policy [text block]" } }, "en": { "role": { "documentation": "The disclosure of a voluntary change in accounting policy." } } }, "auth_ref": [ "r62", "r157" ] }, "pbm_DigitalAssetDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DigitalAssetDeposits", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/DigitalAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposited digital asset", "documentation": "Amount of digital asset deposits.", "label": "Digital Asset Deposits" } } }, "auth_ref": [] }, "pbm_DigitalAssetHoldingsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DigitalAssetHoldingsLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Digital Asset Holdings [Line Items]" } } }, "auth_ref": [] }, "pbm_DigitalAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DigitalAssets", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Digital Assets", "documentation": "Amount of digital assets.", "label": "Digital Assets" } } }, "auth_ref": [] }, "pbm_DigitalAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DigitalAssetsAbstract", "lang": { "en-us": { "role": { "label": "Digital Assets [Abstract]" } } }, "auth_ref": [] }, "pbm_DigitalAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DigitalAssetsAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Digital Assets [Axis]", "label": "Digital Assets Axis" } } }, "auth_ref": [] }, "pbm_DigitalAssetsDomainDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DigitalAssetsDomainDomain", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "label": "DigitalAssetsDomain [Domain]" } } }, "auth_ref": [] }, "pbm_DigitalAssetsScheduleofDigitalAssetHoldingsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DigitalAssetsScheduleofDigitalAssetHoldingsDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "label": "Digital Assets - Schedule of Digital Asset Holdings (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Income/(Loss) per share - diluted (in Dollars per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r39", "r40" ] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/CriticalAccountingEstimatesandJudgements" ], "lang": { "en-us": { "role": { "terseLabel": "Critical accounting estimates and judgements", "label": "Disclosure of accounting judgements and estimates [text block]" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r332" ] }, "pbm_DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatoryTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/AccountsPayableandAccruedLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "\u200bSchedule of Accounts Payable and Accrued Liabilities", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Disclosure Of Accounts Payable And Accrued Liabilities Explanatory Table Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Key Management Personnel [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAssetsAndLiabilitiesAffectedByCurrencyNotBeingExchangeableLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAssetsAndLiabilitiesAffectedByCurrencyNotBeingExchangeableLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable" ], "lang": { "en-us": { "role": { "label": "\u200bSchedule of Change in Presentation Currency [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/BasisofPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of presentation", "label": "Disclosure of basis of preparation of financial statements [text block]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "label": "Disclosure of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfChangesInAccountingEstimatesAbstract", "lang": { "en-us": { "role": { "label": "Critical Accounting Estimates and Judgements [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Effective January 1, 2024 and issued but not yet effective", "label": "Disclosure of changes in accounting policies [text block]" } }, "en": { "role": { "documentation": "The disclosure of changes made to accounting policies by the entity." } } }, "auth_ref": [ "r332" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Share Capital [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable", "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Warrants were Outstanding and Exercisable [Line Items]", "terseLabel": "Share Capital [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "pbm_DisclosureOfCommonSharesWarrantsInputsUsedInFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfCommonSharesWarrantsInputsUsedInFairValueMeasurementExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Allocation", "documentation": "The disclosure of Common Shares Warrants inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value.", "label": "Disclosure Of Common Shares Warrants Inputs Used In Fair Value Measurement Explanatory" } } }, "auth_ref": [] }, "pbm_DisclosureOfConvertibleNoteLiabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfConvertibleNoteLiabilityTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiability" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible note liability", "documentation": "The entire disclosure of Convertible note liability.", "label": "Disclosure Of Convertible Note Liability Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDeferredTaxesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDeferredTaxesExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/IncomeTaxNoteTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Deferred Tax", "label": "Disclosure of deferred taxes [text block]" } }, "en": { "role": { "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative warrant liabilities", "label": "Disclosure of derivative financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Note Liability [Line Items]", "terseLabel": "Promissory Notes [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturity of the Contractual Obligations", "label": "Disclosure of detailed information about financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r117", "r120", "r126", "r204" ] }, "pbm_DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfDetailedInformationAboutPrepaidExpensesExplanatoryTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/PrepaidExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid Expenses", "documentation": "The disclosure of transactions between the entity and its prepaid expenses. [Refer: Total for all related parties [member]]", "label": "Disclosure Of Detailed Information About Prepaid Expenses Explanatory Table Text Block" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/EquipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equipment", "label": "Disclosure of detailed information about property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r13", "r171" ] }, "pbm_DisclosureOfDigitalAssetHoldingsExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfDigitalAssetHoldingsExplanatoryTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/DigitalAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Digital Asset Holdings", "documentation": "The detailed information of digital asset holdings.", "label": "Disclosure Of Digital Asset Holdings Explanatory Text Block" } } }, "auth_ref": [] }, "pbm_DisclosureOfDigitalAssets": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfDigitalAssets", "presentation": [ "http://www.psyencebiomed.com/role/DigitalAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Digital Assets", "documentation": "The entire disclosure for digital assets.", "label": "Disclosure Of Digital Assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Disclosure of events after reporting period [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r1" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Warrant Liability", "label": "Disclosure of fair value measurement of liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value measurement of liabilities." } } }, "auth_ref": [ "r85", "r215" ] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Value of the Financial Instruments", "label": "Disclosure of fair value of financial instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Financial Instruments and Financial Risk Management [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Carrying Value of the Financial Instruments [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagement" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments and financial risk management", "label": "Disclosure of financial risk management [text block]" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r332" ] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/NatureofOperationsandGoingConcern" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of operations and going concern", "label": "Disclosure of general information about financial statements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r146", "r228" ] }, "ifrs-full_DisclosureOfGeographicalAreasLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Non-Capital Loss Carry Forwards [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/IncomeTaxNote" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax note", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r8" ] }, "ifrs-full_DisclosureOfInformationAboutExpectedRecognitionOfContractualServiceMarginInProfitOrLossLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutExpectedRecognitionOfContractualServiceMarginInProfitOrLossLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturity of the Contractual Obligations [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/TransactionswithRelatedPartiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Key Management Personnel", "label": "Disclosure of information about key management personnel [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofRestrictedStockUnitsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Units [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInvestmentPropertyLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInvestmentPropertyLineItems", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "label": "Psyence Labs Ltd. Investment and Investment in Associate [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIssuedCapitalExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapital" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Disclosure of issued capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r332" ] }, "pbm_DisclosureOfLoanProceeds": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfLoanProceeds", "presentation": [ "http://www.psyencebiomed.com/role/LoanReceivableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loan Proceeds", "documentation": "The disclosure of loan proceeds.", "label": "Disclosure Of Loan Proceeds" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/MaterialAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Material accounting policies", "label": "Disclosure of material accounting policy information [text block]" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r154", "r219", "r226" ] }, "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis for derivative financial liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/AccountsPayableandAccruedLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Disclosure of other current liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingExpenseExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/OtherExpense" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense", "label": "Disclosure of other operating expense [text block]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/OtherIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Disclosure of other operating income [text block]" } } }, "auth_ref": [ "r332" ] }, "pbm_DisclosureOfPrefundedWarrantsUsedInFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfPrefundedWarrantsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pre-funded Warrants", "documentation": "The disclosure of pre-funded Warrants inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value.", "label": "Disclosure Of Prefunded Warrants Used In Fair Value Measurement Of Liabilities Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPrepaymentsAndOtherAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPrepaymentsAndOtherAssetsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/PrepaidExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Disclosure of prepayments and other assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of prepayments and other assets. [Refer: Other assets; Prepayments]" } } }, "auth_ref": [ "r332" ] }, "pbm_DisclosureOfPrivatePlacementAndWarrantsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfPrivatePlacementAndWarrantsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrants" ], "lang": { "en-us": { "role": { "terseLabel": "PIPE Financing - Private Placement and Warrants", "documentation": "The entire disclosure for private placement and warrants.", "label": "Disclosure Of Private Placement And Warrants Explanatory" } } }, "auth_ref": [] }, "pbm_DisclosureOfPrivateWarrantExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfPrivateWarrantExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Private Warrants", "documentation": "The disclosure of private warrant.", "label": "Disclosure Of Private Warrant Explanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/Equipment" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment", "label": "Disclosure of property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r16" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Equipment [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "pbm_DisclosureOfPsyenceLabsLtdInvestmentAndInvestmentInAssociate": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfPsyenceLabsLtdInvestmentAndInvestmentInAssociate", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociate" ], "lang": { "en-us": { "role": { "terseLabel": "Psyence Labs Ltd. Investment and Investment in Associate", "documentation": "The entire disclosure for Psyence Labs Ltd. Investment and Investment in Associate.", "label": "Disclosure Of Psyence Labs Ltd Investment And Investment In Associate" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRedesignatedFinancialAssetsAndLiabilitiesLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Classification and Measurements of Financial Assets and Liabilities [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/TransactionswithRelatedParties" ], "lang": { "en-us": { "role": { "terseLabel": "Transactions with related parties", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r28" ] }, "ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRestrictedCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalents" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, restricted cash and cash equivalents", "label": "Disclosure of restricted cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The disclosure of restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } } }, "auth_ref": [ "r332" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/BasisofPresentationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Subsidiaries", "label": "Disclosure of subsidiaries [text block]" } }, "en": { "role": { "documentation": "The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r35", "r38", "r80", "r211" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Subsidiaries [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Pre-funded Warrants [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Using the Black-Scholes Pricing Model", "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities." } } }, "auth_ref": [ "r83" ] }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Private Warrants [Line Items]", "terseLabel": "Schedule of Using the Black-Scholes Pricing Model [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "presentation": [ "http://www.psyencebiomed.com/role/IncomeTaxNoteTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unrecognized Deferred Tax Assets", "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]" } }, "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } } }, "auth_ref": [ "r7", "r166" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.psyencebiomed.com/role/IncomeTaxNoteDetails", "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Unrecognized Deferred Tax Assets [Line Items]", "terseLabel": "Income Tax Note [Line Items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "pbm_DisclosureOfTotalManagedCapitalTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfTotalManagedCapitalTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/CapitalManagementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Managed Capital", "documentation": "Schedule disclosing information related to total managed capital.", "label": "Disclosure Of Total Managed Capital Table Text Block" } } }, "auth_ref": [] }, "pbm_DisclosureOfWarrantsExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfWarrantsExplanatoryTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrant Transactions", "documentation": "Tabular disclosure of the warrants transactions and the number of warrants outstanding.", "label": "Disclosure Of Warrants Explanatory Table Text Block" } } }, "auth_ref": [] }, "pbm_DisclosureOfWarrantsOutstandingAndExercisableExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DisclosureOfWarrantsOutstandingAndExercisableExplanatoryTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrants Outstanding and Exercisable", "documentation": "Tabular disclosure of the warrants outstanding and exercisable.", "label": "Disclosure Of Warrants Outstanding And Exercisable Explanatory Table Text Block" } } }, "auth_ref": [] }, "pbm_DiscountRateSharesMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DiscountRateSharesMeasurementInputMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate shares [Member]", "documentation": "This member stands for a discount rate, shares used as a measurement input used in valuation techniques based on a present value calculation.", "label": "Discount Rate Shares Measurement Input Member" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r290" ] }, "pbm_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "DocumentAndEntityInformationAbstract", "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r289", "r290", "r299" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r289", "r290", "r299", "r301" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r285" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r290" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r300" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "pbm_ELOCAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ELOCAbstract", "lang": { "en-us": { "role": { "label": "ELOC [Abstract]" } } }, "auth_ref": [] }, "pbm_ELOCDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ELOCDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ELOCDetails" ], "lang": { "en-us": { "role": { "label": "ELOC (Details) [Table]" } } }, "auth_ref": [] }, "pbm_ELOCLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ELOCLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ELOCDetails" ], "lang": { "en-us": { "role": { "label": "ELOC [Line Items]" } } }, "auth_ref": [] }, "pbm_ELOCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ELOCMember", "presentation": [ "http://www.psyencebiomed.com/role/ELOCDetails", "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ELOC [Member]", "label": "ELOCMember" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r287" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r287" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r315" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r287" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r312" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r287" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r287" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r314" ] }, "pbm_EquipmentScheduleofEquipmentDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "EquipmentScheduleofEquipmentDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Equipment - Schedule of Equipment (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 }, "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable", "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL SHAREHOLDERS\u2019 EQUITY", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "terseLabel": "NET DEFICIT", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r65", "r68", "r81", "r82", "r84", "r179", "r190", "r213", "r214", "r220", "r235", "r241" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable" ], "lang": { "en-us": { "role": { "terseLabel": "SHAREHOLDERS\u2019 EQUITY", "verboseLabel": "EQUITY", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS EQUITY", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r235" ] }, "ifrs-full_EquityAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net equity", "label": "Equity attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } } }, "auth_ref": [ "r234" ] }, "pbm_EquityLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "EquityLineOfCredit", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ELOCDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity line of credit", "documentation": "The amount of equity line of credit.", "label": "Equity Line Of Credit" } } }, "auth_ref": [] }, "pbm_EquityLineOfCreditDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "EquityLineOfCreditDisclosureTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/ELOC" ], "lang": { "en-us": { "role": { "terseLabel": "ELOC", "documentation": "The entire disclosure of equity line of credit.", "label": "Equity Line Of Credit Disclosure Text Block" } } }, "auth_ref": [] }, "pbm_EthereumMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "EthereumMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Ethereum [Member]", "label": "Ethereum Member" } } }, "auth_ref": [] }, "pbm_ExercisePriceMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExercisePriceMeasurementInputMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price\t[Member]", "verboseLabel": "Exercise Price, Measurement Input [Member]", "documentation": "This member stands for exercise price used as a measurement input.", "label": "Exercise Price Measurement Input Member" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExercisePriceOfOutstandingShareOptions2019", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price, Beginning", "periodEndLabel": "Weighted Average Exercise Price, Ending", "terseLabel": "Weighted Average Exercise Price, Ending", "label": "Exercise price of outstanding share options" } }, "en": { "role": { "documentation": "The exercise price of outstanding share options." } } }, "auth_ref": [ "r102" ] }, "pbm_ExercisePriceWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExercisePriceWarrantMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price\t[Member]", "label": "Exercise Price Warrant Member" } } }, "auth_ref": [] }, "pbm_ExpectedDividendYieldMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExpectedDividendYieldMeasurementInputMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield [Member]", "verboseLabel": "Expected Dividend Yield, Measurement Input [Member]", "documentation": "This member stands for expected dividend yield used as a measurement input.", "label": "Expected Dividend Yield Measurement Input Member" } } }, "auth_ref": [] }, "pbm_ExpectedDividendYieldWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExpectedDividendYieldWarrantMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield [Member]", "label": "Expected Dividend Yield Warrant Member" } } }, "auth_ref": [] }, "pbm_ExpectedLife": { "xbrltype": "durationItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExpectedLife", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life", "documentation": "Expected life.", "label": "Expected Life" } } }, "auth_ref": [] }, "pbm_ExpectedLifeMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExpectedLifeMeasurementInputMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life [Member]", "documentation": "This member stands for expected life used as a measurement input.", "label": "Expected Life Measurement Input Member" } } }, "auth_ref": [] }, "pbm_ExpectedLifeWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExpectedLifeWarrantMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life [Member]", "label": "Expected Life Warrant Member" } } }, "auth_ref": [] }, "pbm_ExpectedVolatilityWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExpectedVolatilityWarrantMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility [Member]", "label": "Expected Volatility Warrant Member" } } }, "auth_ref": [] }, "ifrs-full_ExpenseByNatureAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseByNatureAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "label": "Schedule of Listing Expenses [Abstract]", "terseLabel": "Expenses" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payments (in Dollars)", "label": "Expense from share-based payment transactions" } } }, "auth_ref": [ "r107", "r199" ] }, "pbm_ExpiryDateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExpiryDateMeasurementInputMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expiry date [Member]", "label": "Expiry Date Measurement Input Member" } } }, "auth_ref": [] }, "pbm_ExpiryDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExpiryDateMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expiry date [Member]", "label": "Expiry Date Member" } } }, "auth_ref": [] }, "pbm_ExpiryDateWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExpiryDateWarrantMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expiry date [Member]", "label": "Expiry Date Warrant Member" } } }, "auth_ref": [] }, "pbm_ExtinguishmentOfDebtEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ExtinguishmentOfDebtEquity", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extinguishment amount", "documentation": "The amount of extinguishment of debt equity.", "label": "Extinguishment Of Debt Equity" } } }, "auth_ref": [] }, "pbm_FairValueAdjustmentOnConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValueAdjustmentOnConvertibleNote", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow", "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value (gain)/loss on convertible note", "negatedLabel": "Fair value gain/(loss) on convertible note", "documentation": "Amount of expense (income) related to adjustment to fair value of convertible note.", "label": "Fair Value Adjustment On Convertible Note" } } }, "auth_ref": [] }, "pbm_FairValueAdjustmentOnPromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValueAdjustmentOnPromissoryNote", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement", "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Fair value gain/(loss) on promissory notes", "terseLabel": "Fair value gain", "documentation": "Amount of expense (income) related to adjustment to fair value of promissory note.", "label": "Fair Value Adjustment On Promissory Note" } } }, "auth_ref": [] }, "pbm_FairValueAdjustmentsOnPromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValueAdjustmentsOnPromissoryNote", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value (gain)/loss on promissory notes", "documentation": "Amount of expense (income) related to adjustment to fair\r\n value of promissory note.", "label": "Fair Value Adjustments On Promissory Note" } } }, "auth_ref": [] }, "pbm_FairValueAllocationAssumptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValueAllocationAssumptionsMember", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Allocation Assumptions [Member]", "label": "Fair Value Allocation Assumptions Member" } } }, "auth_ref": [] }, "pbm_FairValueAllocationGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValueAllocationGrossProceeds", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails", "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total gross proceeds", "terseLabel": "Gross proceeds", "documentation": "It represents fair value allocation on gross proceeds.", "label": "Fair Value Allocation Gross Proceeds" } } }, "auth_ref": [] }, "pbm_FairValueGainOnInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValueGainOnInvestment", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value gain on investment in Psyence Labs Ltd", "documentation": "The amount of fair value gain on investment.", "label": "Fair Value Gain On Investment" } } }, "auth_ref": [] }, "pbm_FairValueGainOnPsyenceLabsLtd": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValueGainOnPsyenceLabsLtd", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Fair value gain on Psyence Labs Ltd", "documentation": "Amount of income related to adjustment to fair value of psyence labs ltd.", "label": "Fair Value Gain On Psyence Labs Ltd" } } }, "auth_ref": [] }, "pbm_FairValueLossOnDigitalAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValueLossOnDigitalAssets", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Fair value loss on digital assets", "documentation": "Amount of fair value loss on digital assets.", "label": "Fair Value Loss On Digital Assets" } } }, "auth_ref": [] }, "pbm_FairValueLossOnWarrantExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValueLossOnWarrantExchange", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement", "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Fair value loss on warrant exchange", "terseLabel": "Fair value (loss)/gain on warrant liability (in Dollars)", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant exchange.", "label": "Fair Value Loss On Warrant Exchange" } } }, "auth_ref": [] }, "pbm_FairValueOfDigitalAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValueOfDigitalAsset", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "documentation": "Amount of fair value.", "label": "Fair Value Of Digital Asset" } } }, "auth_ref": [] }, "pbm_FairValuePerUnitOfDigitalAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValuePerUnitOfDigitalAsset", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value per Unit", "documentation": "Amount of fair value per unit.", "label": "Fair Value Per Unit Of Digital Asset" } } }, "auth_ref": [] }, "pbm_FairValuegainlossOnWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValuegainlossOnWarrantLiability", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow", "http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value loss/(gain) on warrant liability", "verboseLabel": "Amount, Fair value gain (loss)", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Valuegainloss On Warrant Liability" } } }, "auth_ref": [] }, "pbm_FairValuesLossOnWarrantExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FairValuesLossOnWarrantExchange", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value loss on warrant exchange", "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]", "label": "Fair Values Loss On Warrant Exchange" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments at fair value assets", "label": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r116" ] }, "pbm_FinancialInstrumentsandFinancialRiskManagementScheduleofCarryingValueoftheFinancialInstrumentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FinancialInstrumentsandFinancialRiskManagementScheduleofCarryingValueoftheFinancialInstrumentsDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "label": "Financial Instruments and Financial Risk Management - Schedule of Carrying Value of the Financial Instruments (Details) [Table]" } } }, "auth_ref": [] }, "pbm_FinancialInstrumentsandFinancialRiskManagementScheduleofMaturityoftheContractualObligationsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FinancialInstrumentsandFinancialRiskManagementScheduleofMaturityoftheContractualObligationsDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable" ], "lang": { "en-us": { "role": { "label": "Financial Instruments and Financial Risk Management - Schedule of Maturity of the Contractual Obligations (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r116" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/PromissoryNotesDetails", "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments at fair value liabilities", "verboseLabel": "Fair value of warrants (in Dollars)", "netLabel": "Fair value", "label": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r116" ] }, "pbm_FinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual Cash Flows", "documentation": "The amount of contractual undiscounted cash flows in relation to financial liabilities.", "label": "Financial Liabilities Undiscounted Cash Flows" } } }, "auth_ref": [] }, "pbm_FirstTrancheNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FirstTrancheNoteMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Tranche Note [Member]", "documentation": "This member stands for First tranche note.", "label": "First Tranche Note Member" } } }, "auth_ref": [] }, "pbm_FirstTrancheNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FirstTrancheNotesMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Tranche Notes [Member]", "label": "First Tranche Notes Member" } } }, "auth_ref": [] }, "pbm_FixedConsiderationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "FixedConsiderationAmount", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed consideration amount", "documentation": "The amount of fixed consideration.", "label": "Fixed Consideration Amount" } } }, "auth_ref": [] }, "pbm_ForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ForecastMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast Member" } } }, "auth_ref": [] }, "pbm_GainOnDebtSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "GainOnDebtSettlement", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on debt settlement", "documentation": "Represents the value of gain on debt settlement.", "label": "Gain On Debt Settlement" } } }, "auth_ref": [] }, "pbm_GainOnDebtSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "GainOnDebtSettlements", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on debt settlement", "documentation": "The amount of gain on debt settlement.", "label": "Gain On Debt Settlements" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnChangeInFairValueOfDerivatives", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value loss (in Dollars)", "label": "Gains (losses) on change in fair value of derivatives" } }, "en": { "role": { "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r341" ] }, "ifrs-full_GainsLossesOnDisposalsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnDisposalsOfInvestments", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment in Digital Assets", "label": "Gains (losses) on disposals of investments" } }, "en": { "role": { "documentation": "The gains (losses) on disposals of investments." } } }, "auth_ref": [ "r250" ] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange loss", "label": "Foreign exchange gain (loss)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r19", "r173", "r227" ] }, "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-taxable fair value gain adjustment", "label": "Gains (losses) on financial assets at fair value through profit or loss" } }, "en": { "role": { "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r114", "r206" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and administrative expenses, operating" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.psyencebiomed.com/role/IncomeTaxNoteDetails", "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable", "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r137", "r253", "r264", "r266", "r274" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r137", "r253", "r264", "r266", "r274" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cost [Member]", "label": "Gross carrying amount [member]" } } }, "auth_ref": [ "r9", "r45", "r50", "r53", "r112", "r119", "r121", "r167", "r182", "r186", "r189", "r209", "r210", "r267" ] }, "pbm_GrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "GrossProceeds", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds (in Dollars)", "documentation": "The amount of gross proceeds.", "label": "Gross Proceeds" } } }, "auth_ref": [] }, "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "HistoricalVolatilityForSharesMeasurementInputMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility [Member]", "label": "Historical volatility for shares, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for the historical volatility for shares used as a measurement input." } } }, "auth_ref": [ "r261" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r289", "r290", "r299" ] }, "pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IfrsAccountsPayableAndAccruedLiabilitiesMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable & accrued liabilities [Member]", "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Ifrs Accounts Payable And Accrued Liabilities Member" } } }, "auth_ref": [] }, "pbm_IfrsClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IfrsClassOfWarrantOrRightAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Ifrs Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued.", "label": "Ifrs Class Of Warrant Or Right Axis" } } }, "auth_ref": [] }, "pbm_IfrsClassOfWarrantOrRightDomainDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IfrsClassOfWarrantOrRightDomainDomain", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "label": "IfrsClassOfWarrantOrRightDomain [Domain]" } } }, "auth_ref": [] }, "pbm_IfrsFairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IfrsFairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Fair value gain/(loss) on warrant liability", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Ifrs Fair Value Adjustment Of Warrants" } } }, "auth_ref": [] }, "pbm_IfrsGainLossOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IfrsGainLossOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on debt settlement (in Dollars)", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Ifrs Gain Loss On Extinguishment Of Debt" } } }, "auth_ref": [] }, "pbm_IfrsTaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IfrsTaxPeriodAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable", "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable" ], "lang": { "en-us": { "role": { "terseLabel": "IFRS Tax Period [Axis]", "documentation": "N/A", "label": "Ifrs Tax Period Axis" } } }, "auth_ref": [] }, "pbm_IfrsTaxPeriodDomainDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IfrsTaxPeriodDomainDomain", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable" ], "lang": { "en-us": { "role": { "label": "IfrsTaxPeriodDomain [Domain]" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "totalLabel": "Income tax (recovery)/expense", "label": "Income tax expense (income), income taxes" } } }, "auth_ref": [ "r2", "r3", "r4", "r31", "r79", "r131", "r161", "r162", "r163", "r248" ] }, "pbm_IncomeTaxNoteDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IncomeTaxNoteDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/IncomeTaxNoteDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Note (Details) [Table]" } } }, "auth_ref": [] }, "pbm_IncomeTaxNoteScheduleofNonCapitalLossCarryForwardsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IncomeTaxNoteScheduleofNonCapitalLossCarryForwardsDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable" ], "lang": { "en-us": { "role": { "label": "Income Tax Note - Schedule of Non-Capital Loss Carry Forwards (Details) [Table]" } } }, "auth_ref": [] }, "pbm_IncomeTaxNoteScheduleofUnrecognizedDeferredTaxAssetsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IncomeTaxNoteScheduleofUnrecognizedDeferredTaxAssetsDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "label": "Income Tax Note - Schedule of Unrecognized Deferred Tax Assets (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable" ], "lang": { "en-us": { "role": { "terseLabel": "Reported [Member]", "label": "Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Change in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r56", "r151" ] }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Shares issued for PsyLabs share exchange", "label": "Increase (decrease) in number of ordinary shares issued" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r335" ] }, "pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact to net loss and comprehensive loss", "documentation": "The increase (decrease) in profit and loss as a result of an change in a designated risk component that was reasonably possible at the end of the reporting period. Excludes defined benefit plan obligations.", "label": "Increase Decrease In Profit Or Loss Due To Reasonably Possible Change In Designated Risk Component" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for warrant conversion", "verboseLabel": "Equity on conversion", "label": "Increase (decrease) through conversion of convertible instruments, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } } }, "auth_ref": [ "r333" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of warrants", "label": "Increase (decrease) through exercise of warrants, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r333" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r224" ] }, "ifrs-full_IncrementalFairValueGrantedModifiedSharebasedPaymentArrangements": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncrementalFairValueGrantedModifiedSharebasedPaymentArrangements", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value (in Dollars)", "label": "Incremental fair value granted, modified share-based payment arrangements" } }, "en": { "role": { "documentation": "The difference, for modified share-based payment arrangements, between the fair value of the modified equity instrument and that of the original equity instrument, both estimated as at the date of the modification. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r106" ] }, "pbm_IndefinitePeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IndefinitePeriodMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite [Member]", "documentation": "Represents the indefinite period.", "label": "Indefinite Period Member" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r302" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted [Flag]", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r291", "r304" ] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest expense" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r78", "r129", "r136" ] }, "ifrs-full_InterestRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestRateMeasurementInputMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate [Member]", "label": "Interest rate, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for an interest rate used as a measurement input." } } }, "auth_ref": [ "r260" ] }, "ifrs-full_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestReceivable", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofLoanProceedsTable": { "parentTag": "ifrs-full_LoansAndAdvancesToCustomers", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofLoanProceedsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest receivable", "label": "Interest receivable" } }, "en": { "role": { "documentation": "The amount of interest recognised as a receivable." } } }, "auth_ref": [ "r335" ] }, "pbm_InvestmentInAssociateAtAcquisitionDate": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "InvestmentInAssociateAtAcquisitionDate", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingAmountofInvestmentTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total \u2013 Investment in Associate at Acquisition Date, Shares (in Shares)", "documentation": "The number of investment in associate at acquisition date.", "label": "Investment In Associate At Acquisition Date" } } }, "auth_ref": [] }, "pbm_InvestmentInDigitalAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "InvestmentInDigitalAssetsMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in digital assets [Member]", "label": "Investment In Digital Assets Member" } } }, "auth_ref": [] }, "pbm_InvestmentInPsyenceLabsLtd": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "InvestmentInPsyenceLabsLtd", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Psyence Labs Ltd", "documentation": "Amount of investment in psyence labs ltd.", "label": "Investment In Psyence Labs Ltd" } } }, "auth_ref": [] }, "pbm_InvestmentInPsyenceLabsLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "InvestmentInPsyenceLabsLtdMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable", "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Psyence Labs Ltd [Member]", "label": "Investment In Psyence Labs Ltd Member" } } }, "auth_ref": [] }, "ifrs-full_InvestmentPropertyAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentPropertyAbstract", "lang": { "en-us": { "role": { "label": "Psyence Labs Ltd. Investment and Investment in Associate [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_InvestmentPropertyFairValueUsedAsDeemedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentPropertyFairValueUsedAsDeemedCost", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of investment", "label": "Investment property fair value used as deemed cost" } } }, "auth_ref": [ "r67" ] }, "ifrs-full_InvestmentsInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentsInAssociates", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "http://www.psyencebiomed.com/role/ScheduleofCarryingAmountofInvestmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Associate", "verboseLabel": "Investment in associate at Acquisition Date (February 25, 2026)", "netLabel": "Carrying amount at March 31, 2026", "label": "Investments in associates reported in separate financial statements" } }, "en": { "role": { "documentation": "The amount of investments in associates in an entity's separate financial statements. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r32" ] }, "pbm_InvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "InvestorsMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investors [Member]", "documentation": "This member stands for investors.", "label": "Investors Member" } } }, "auth_ref": [] }, "pbm_IssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IssuanceCosts", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ELOCDetails", "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance costs", "documentation": "The amount of issuance costs.", "label": "Issuance Costs" } } }, "auth_ref": [] }, "pbm_IssuanceOfSharesForInvestmentInAssociate": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IssuanceOfSharesForInvestmentInAssociate", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for investment in Associate (in Shares)", "documentation": "Issuance of shares for investment in Associate.", "label": "Issuance Of Shares For Investment In Associate" } } }, "auth_ref": [] }, "pbm_IssuanceOfSharesOnExerciseOfRSUs": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IssuanceOfSharesOnExerciseOfRSUs", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares on exercise of RSUs", "documentation": "Issuance of shares on exercise of RSUs.", "label": "Issuance Of Shares On Exercise Of RSUs" } } }, "auth_ref": [] }, "pbm_IssuanceOfSharesOnExerciseOfRSUsinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IssuanceOfSharesOnExerciseOfRSUsinShares", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares on exercise of RSUs (in Shares)", "documentation": "Issuance of shares on exercise of RSUs.", "label": "Issuance Of Shares On Exercise Of RSUsin Shares" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable", "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares to Psyence Group Inc", "verboseLabel": "Deemed consideration amount for the common shares issued", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r224" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 }, "http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable": { "parentTag": "ifrs-full_CurrentFinancialLiabilitiesAtAmortisedCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails", "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable", "http://www.psyencebiomed.com/role/ScheduleofTotalManagedCapitalTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Amount of Common shares, Opening balance (in Dollars)", "periodEndLabel": "Amount of Common shares, Ending Balance (in Dollars)", "terseLabel": "Share Capital", "verboseLabel": "Share capital", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r277", "r282" ] }, "pbm_IssuedCapital1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "IssuedCapital1Member", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Issued Capital [Member]", "label": "Issued Capital1 Member" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalAbstract", "lang": { "en-us": { "role": { "label": "Capital Management [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r225" ] }, "ifrs-full_IssuedCapitalOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalOrdinaryShares", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable": { "parentTag": "pbm_FairValueAllocationGrossProceeds", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails", "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares", "verboseLabel": "Fair value of shares issued", "label": "Issued capital, ordinary shares" } }, "en": { "role": { "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]" } } }, "auth_ref": [ "r338" ] }, "pbm_KAOSGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "KAOSGroupMember", "presentation": [ "http://www.psyencebiomed.com/role/OtherExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "KAOS Group [Member]", "label": "KAOSGroup Member" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Key management personnel compensation, operating" } } }, "auth_ref": [ "r23", "r175" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Key management personnel compensation, share-based payment" } } }, "auth_ref": [ "r22" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofKeyManagementPersonnelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Short term benefits", "label": "Key management personnel compensation, short-term employee benefits, operating" } } }, "auth_ref": [ "r21" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "\u200bBetween 1 and 3 years [Member]", "label": "Later than one year and not later than three years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than three years." } } }, "auth_ref": [ "r268", "r269", "r271" ] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1 [Member]", "label": "Level 1 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r17", "r43", "r44", "r82", "r181", "r214" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2 [Member]", "label": "Level 2 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r43", "r44", "r82", "r181", "r214" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3 [Member]", "label": "Level 3 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r43", "r44", "r82", "r181", "r214" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r17", "r82", "r214" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r17", "r82", "r214" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r81", "r82", "r84", "r132", "r135", "r213", "r214", "r235" ] }, "pbm_ListingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ListingExpense", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Listing expense", "documentation": "The amount of listing expense.", "label": "Listing Expense" } } }, "auth_ref": [] }, "pbm_LoanCarryingAmountAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "LoanCarryingAmountAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofLoanProceedsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loan Carrying Amount", "label": "Loan Carrying Amount Abstract" } } }, "auth_ref": [] }, "pbm_LoanPrincipals": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "LoanPrincipals", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofLoanProceedsTable": { "parentTag": "ifrs-full_LoansAndAdvancesToCustomers", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofLoanProceedsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loan principal", "documentation": "The amount of loan principal.", "label": "Loan Principals" } } }, "auth_ref": [] }, "pbm_LoanReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "LoanReceivableMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loan receivable [Member]", "label": "Loan Receivable Member" } } }, "auth_ref": [] }, "pbm_LoanReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "LoanReceivableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/LoanReceivable" ], "lang": { "en-us": { "role": { "terseLabel": "Loan Receivable", "documentation": "The entire disclosure of loan receivable.", "label": "Loan Receivable Text Block" } } }, "auth_ref": [] }, "ifrs-full_LoansAndAdvances": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LoansAndAdvances", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/LoanReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advanced loan", "label": "Loans and advances" } }, "en": { "role": { "documentation": "The amount of loans and advances the entity has made." } } }, "auth_ref": [ "r337" ] }, "ifrs-full_LoansAndAdvancesToCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LoansAndAdvancesToCustomers", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 }, "http://www.psyencebiomed.com/role/ScheduleofLoanProceedsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "http://www.psyencebiomed.com/role/ScheduleofLoanProceedsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Loan receivable", "terseLabel": "Loan receivable", "label": "Loans and advances to customers" } }, "en": { "role": { "documentation": "The amount of loans and advances the entity has made to customers." } } }, "auth_ref": [ "r337" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Note [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MajorOrdinaryShareTransactionsMember", "presentation": [ "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Member]", "label": "Major ordinary share transactions [member]" } }, "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r252", "r275" ] }, "pbm_MaterialAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "MaterialAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Material Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "pbm_MaterialAccountingPoliciesScheduleofChangeinPresentationCurrencyDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "MaterialAccountingPoliciesScheduleofChangeinPresentationCurrencyDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable" ], "lang": { "en-us": { "role": { "label": "Material Accounting Policies - \u200bSchedule of Change in Presentation Currency (Details) [Table]" } } }, "auth_ref": [] }, "pbm_MaterialAccountingPoliciesScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "MaterialAccountingPoliciesScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "label": "Material Accounting Policies - Schedule of Classification and Measurements of Financial Assets and Liabilities (Details) [Table]" } } }, "auth_ref": [] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r87", "r88", "r89", "r90", "r91", "r92", "r93", "r115", "r123", "r140", "r141", "r143", "r145", "r207", "r238", "r254", "r268" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable" ], "lang": { "en-us": { "role": { "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r87", "r88", "r89", "r90", "r91", "r92", "r93", "r115", "r140", "r141", "r143", "r145", "r207", "r238", "r254", "r268", "r270" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]" } } }, "auth_ref": [] }, "pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram": { "xbrltype": "percentItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram", "presentation": [ "http://www.psyencebiomed.com/role/OtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses percentage", "documentation": "The maximum percentage of rebate for the research & development expenses under the research & development tax incentive program.", "label": "Maximum Percentage Of Rebate On Research Development Tax Incentive Program" } } }, "auth_ref": [] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable" ], "lang": { "en-us": { "role": { "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r48", "r52", "r81", "r188", "r213" ] }, "pbm_MeasurementsOfFinancialAssetsAndLiabilities": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "MeasurementsOfFinancialAssetsAndLiabilities", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement", "documentation": "measurements of financial assets and liabilities.", "label": "Measurements Of Financial Assets And Liabilities" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [] }, "pbm_NCACNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NCACNoteMember", "presentation": [ "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NCAC Note [Member]", "label": "NCACNote Member" } } }, "auth_ref": [] }, "pbm_NatureOfOperationsAndGoingConcernAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NatureOfOperationsAndGoingConcernAbstract", "lang": { "en-us": { "role": { "label": "Nature of Operations and Going Concern [Abstract]" } } }, "auth_ref": [] }, "pbm_NcacMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NcacMember", "presentation": [ "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails", "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable", "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NCAC [Member]", "documentation": "This member stands for Newcourt Acquisition Corp (NCAC).", "label": "Ncac Member" } } }, "auth_ref": [] }, "ifrs-full_NetAssetsLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetAssetsLiabilities", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net liabilities acquired", "label": "Assets (liabilities)" } }, "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } } }, "auth_ref": [ "r258", "r335" ] }, "pbm_NetIdentifiableLiabilitiesAcquiredAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NetIdentifiableLiabilitiesAcquiredAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net identifiable liabilities acquired:", "label": "Net Identifiable Liabilities Acquired Abstract" } } }, "auth_ref": [] }, "pbm_NetProceedsReceivedFromELOC": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NetProceedsReceivedFromELOC", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds received from ELOC", "documentation": "The cash inflow from received from the of (ELOC) ordinary shares.", "label": "Net Proceeds Received From ELOC" } } }, "auth_ref": [] }, "pbm_NewcourtAcquisitionCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NewcourtAcquisitionCorpMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Newcourt Acquisition Corp. [Member]", "label": "Newcourt Acquisition Corp Member" } } }, "auth_ref": [] }, "pbm_NonCapitalLossCarryForwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NonCapitalLossCarryForwards", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-capital loss carry forwards", "documentation": "Amount of non-capital loss carry forwards.", "label": "Non Capital Loss Carry Forwards" } } }, "auth_ref": [] }, "pbm_NonCapitalLossesCarriedForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NonCapitalLossesCarriedForwardMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-capital losses carried forward [Member]", "label": "Non Capital Losses Carried Forward Member" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails", "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r160" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails", "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r160" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current assets", "label": "Non-current assets [abstract]" } } }, "auth_ref": [] }, "pbm_NondeductibleLossOnLoanSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NondeductibleLossOnLoanSettlement", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-deductible loss on loan settlement", "documentation": "Represent the amount of non-deductible loss on loan settlement.", "label": "Nondeductible Loss On Loan Settlement" } } }, "auth_ref": [] }, "pbm_NondeductibleRampDCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NondeductibleRampDCosts", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-deductible R&D costs", "documentation": "Amount of non-deductible R&D costs.", "label": "Nondeductible Ramp DCosts" } } }, "auth_ref": [] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofMaturityoftheContractualObligationsTable" ], "lang": { "en-us": { "role": { "terseLabel": "\u200bLess than 1 year [Member]", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r88", "r89", "r93", "r142", "r144", "r237", "r268", "r271" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal amount", "verboseLabel": "Principal amount of debt issued", "label": "Notional amount" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r335" ] }, "pbm_NumberOfCommonSharesCommitmentSharesELOC": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesCommitmentSharesELOC", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Commitment shares ELOC", "documentation": "Number of Common shares, Commitment shares ELOC.", "label": "Number Of Common Shares Commitment Shares ELOC" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesExerciseOfRSUs": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesExerciseOfRSUs", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Exercise of RSUs", "documentation": "Number of common shares, exercise of RSUs.", "label": "Number Of Common Shares Exercise Of RSUs" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesShareIssuanceCostsForELOC": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesShareIssuanceCostsForELOC", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Share issuance costs for ELOC", "documentation": "Number of Common shares, Share issuance costs for ELOC.", "label": "Number Of Common Shares Share Issuance Costs For ELOC" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesShareIssuanceCostsForPIPEFinancing": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesShareIssuanceCostsForPIPEFinancing", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Share issuance costs for PIPE financing", "documentation": "Number of Common shares, Share issuance costs for PIPE financing.", "label": "Number Of Common Shares Share Issuance Costs For PIPEFinancing" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesShareIssuanceForAssociate": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesShareIssuanceForAssociate", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Share issuance for Associate", "documentation": "Number of common shares, share issuance for associate.", "label": "Number Of Common Shares Share Issuance For Associate" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesShareIssuanceToNCACShareholders": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesShareIssuanceToNCACShareholders", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Share issuance to NCAC shareholders", "documentation": "Number of Common shares, Share issuance to NCAC shareholders.", "label": "Number Of Common Shares Share Issuance To NCACShareholders" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesShareIssuanceToPGI": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesShareIssuanceToPGI", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Share issuance to PGI", "documentation": "Number of Common shares issuance to PGI.", "label": "Number Of Common Shares Share Issuance To PGI" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesSharesIssuanceCostsForPIPEPrefundedWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesSharesIssuanceCostsForPIPEPrefundedWarrantsExercised", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Shares issuance costs for PIPE pre-funded warrants exercised", "documentation": "Number of Common shares, Shares issuance costs for PIPE pre-funded warrants exercised.", "label": "Number Of Common Shares Shares Issuance Costs For PIPEPrefunded Warrants Exercised" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesSharesIssuedForDebtSettlement": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesSharesIssuedForDebtSettlement", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Shares issued for debt settlement", "documentation": "Number of common shares, shares issued for debt settlement.", "label": "Number Of Common Shares Shares Issued For Debt Settlement" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesSharesIssuedForELOC": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesSharesIssuedForELOC", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Shares issued for ELOC", "documentation": "Number of common shares, shares issued for ELOC.", "label": "Number Of Common Shares Shares Issued For ELOC" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesSharesIssuedForPIPEFinancing": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesSharesIssuedForPIPEFinancing", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Shares issued for PIPE financing", "documentation": "Number of common shares, shares issued for PIPE financing.", "label": "Number Of Common Shares Shares Issued For PIPEFinancing" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesSharesIssuedForPIPEPrefundedWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesSharesIssuedForPIPEPrefundedWarrantsExercised", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Shares issued for PIPE pre-funded warrants exercised", "documentation": "Number of Common shares, Shares issued for PIPE pre-funded warrants exercised.", "label": "Number Of Common Shares Shares Issued For PIPEPrefunded Warrants Exercised" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesSharesIssuedOnConversionOfConvertibleNote": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesSharesIssuedOnConversionOfConvertibleNote", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Shares issued on conversion of convertible note", "documentation": "Number of common shares, shares issued on conversion of convertible note.", "label": "Number Of Common Shares Shares Issued On Conversion Of Convertible Note" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesSharesIssuedOnConversionOfConvertibleNoteWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesSharesIssuedOnConversionOfConvertibleNoteWarrants", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Shares issued on conversion of convertible note warrants", "documentation": "Number of Common shares, Shares issued on conversion of convertible note warrants.", "label": "Number Of Common Shares Shares Issued On Conversion Of Convertible Note Warrants" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesSharesIssuedOnConversionOfNCACPromissoryNotes": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesSharesIssuedOnConversionOfNCACPromissoryNotes", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Shares issued on conversion of NCAC promissory notes", "documentation": "Number of Common shares, Shares issued on conversion of NCAC promissory notes.", "label": "Number Of Common Shares Shares Issued On Conversion Of NCACPromissory Notes" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesSharesIssuedOnConversionOfPGIPromissoryNotes": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesSharesIssuedOnConversionOfPGIPromissoryNotes", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Shares issued on conversion of PGI promissory notes", "documentation": "Number of Common shares, Shares issued on conversion of PGI promissory notes.", "label": "Number Of Common Shares Shares Issued On Conversion Of PGIPromissory Notes" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesSharesIssuedToThirdPartyAdvisors": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesSharesIssuedToThirdPartyAdvisors", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Shares issued to third party advisors", "documentation": "Number of common shares, shares issued to third party advisors.", "label": "Number Of Common Shares Shares Issued To Third Party Advisors" } } }, "auth_ref": [] }, "pbm_NumberOfCommonSharesWarrantExchange": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfCommonSharesWarrantExchange", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Common shares, Warrant exchange", "documentation": "Number of common shares, warrant exchange.", "label": "Number Of Common Shares Warrant Exchange" } } }, "auth_ref": [] }, "pbm_NumberOfExercisedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfExercisedShares", "presentation": [ "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of exercised shares", "documentation": "Number of exercised shares.", "label": "Number Of Exercised Shares" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSU settled shares", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r105", "r330" ] }, "pbm_NumberOfOtherEquityInstrumentsAcceleratedVestingInSharebasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfOtherEquityInstrumentsAcceleratedVestingInSharebasedPaymentArrangement", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs accelerated vesting", "documentation": "The number of other equity instruments accelerated vesting in share-based payment arrangement.", "label": "Number Of Other Equity Instruments Accelerated Vesting In Sharebased Payment Arrangement" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable into common shares", "label": "Number of other equity instruments exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r330" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares exercised", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r330" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs cancelled shares", "label": "Number of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r330" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofRestrictedStockUnitsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Number of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r95", "r99", "r102", "r192", "r196" ] }, "pbm_NumberOfShareIssuedWarrantLiability": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfShareIssuedWarrantLiability", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares, Opening balance", "periodEndLabel": "Number of shares, Balance ending", "documentation": "The number of share issued in warrant liability.", "label": "Number Of Share Issued Warrant Liability" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable per share", "label": "Number of share options exercisable in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r100", "r197" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofRestrictedStockUnitsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised during the year", "label": "Number of share options exercised in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r98", "r195" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofRestrictedStockUnitsTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Cancelled during the year", "label": "Number of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r97", "r194" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofRestrictedStockUnitsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Issued during the year", "label": "Number of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r96", "r193" ] }, "pbm_NumberOfSharesConvertibleNoteTerminationAgreementWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfSharesConvertibleNoteTerminationAgreementWarrantsExercised", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants, Convertible note Termination Agreement warrants exercised", "documentation": "Number of shares convertible note termination agreement warrants exercised.", "label": "Number Of Shares Convertible Note Termination Agreement Warrants Exercised" } } }, "auth_ref": [] }, "pbm_NumberOfSharesInFairValueGainloss": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfSharesInFairValueGainloss", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares, Fair value gain (loss)", "documentation": "The number of share in Fair value gain loss.", "label": "Number Of Shares In Fair Value Gainloss" } } }, "auth_ref": [] }, "pbm_NumberOfSharesIssuanceCostsForPIPEFinancingWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfSharesIssuanceCostsForPIPEFinancingWarrants", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants, Issuance costs for PIPE financing warrants", "documentation": "Number of shares Issuance costs for PIPE financing warrants.", "label": "Number Of Shares Issuance Costs For PIPEFinancing Warrants" } } }, "auth_ref": [] }, "pbm_NumberOfSharesIssuanceCostsForPIPEPrefundedWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfSharesIssuanceCostsForPIPEPrefundedWarrantsExercised", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants, Issuance costs for PIPE pre-funded warrants exercised", "documentation": "Number of shares Issuance costs for PIPE pre-funded warrants exercised.", "label": "Number Of Shares Issuance Costs For PIPEPrefunded Warrants Exercised" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/ELOCDetails", "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails", "http://www.psyencebiomed.com/role/PromissoryNotesDetails", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails", "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails", "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable", "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable", "http://www.psyencebiomed.com/role/ShareCapitalDetails", "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Common shares, Opening balance", "periodEndLabel": "Number of Common shares, Ending Balance", "terseLabel": "Total consideration shares issued (in Shares)", "verboseLabel": "Number of shares issued", "netLabel": "Number of shares issued (in Shares)", "label": "Pre-funded warrants issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r333" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails", "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "terseLabel": "Number of shares outstanding", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r148", "r217", "r243" ] }, "pbm_NumberOfSharesPIPEFinancingWarrantIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfSharesPIPEFinancingWarrantIssuance", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants, PIPE financing warrant issuance", "documentation": "Number of shares PIPE financing warrant issuance.", "label": "Number Of Shares PIPEFinancing Warrant Issuance" } } }, "auth_ref": [] }, "pbm_NumberOfSharesPIPEFinancingWarrantIssuanceCosts": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfSharesPIPEFinancingWarrantIssuanceCosts", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants, PIPE financing warrant issuance costs", "documentation": "Number of shares PIPE financing warrant issuance costs.", "label": "Number Of Shares PIPEFinancing Warrant Issuance Costs" } } }, "auth_ref": [] }, "pbm_NumberOfSharesPIPEPrefundedWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfSharesPIPEPrefundedWarrantsExercised", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants, PIPE pre-funded warrants exercised", "documentation": "Number of shares PIPE pre-funded warrants exercised.", "label": "Number Of Shares PIPEPrefunded Warrants Exercised" } } }, "auth_ref": [] }, "pbm_NumberOfSharesWarrantsIssuedForConvertibleNoteAddendum": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfSharesWarrantsIssuedForConvertibleNoteAddendum", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants, Warrants issued for convertible note Addendum", "documentation": "Number of shares Warrants issued for convertible note Addendum.", "label": "Number Of Shares Warrants Issued For Convertible Note Addendum" } } }, "auth_ref": [] }, "pbm_NumberOfSharesWarrantsIssuedForConvertibleNoteTerminationAgreement": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfSharesWarrantsIssuedForConvertibleNoteTerminationAgreement", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants, Warrants issued for convertible note Termination Agreement", "documentation": "Number of shares warrants issued for convertible note termination agreement.", "label": "Number Of Shares Warrants Issued For Convertible Note Termination Agreement" } } }, "auth_ref": [] }, "pbm_NumberOfWarrantExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfWarrantExercisable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants Exercisable", "documentation": "Represents the number of warrants exercisable.", "label": "Number Of Warrant Exercisable" } } }, "auth_ref": [] }, "pbm_NumberOfWarrantOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfWarrantOutstanding", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants Outstanding", "verboseLabel": "Warrants outstanding", "documentation": "Number of warrants outstanding.", "label": "Number Of Warrant Outstanding" } } }, "auth_ref": [] }, "pbm_NumberOfWarrantPurchased": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfWarrantPurchased", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrant purchased", "documentation": "Number of warrants purchased.", "label": "Number Of Warrant Purchased" } } }, "auth_ref": [] }, "pbm_NumberOfWarrantsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfWarrantsExercisable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants Exercisable", "documentation": "Number of warrants exercisable.", "label": "Number Of Warrants Exercisable" } } }, "auth_ref": [] }, "pbm_NumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfWarrantsIssued", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants issued", "verboseLabel": "Pre-funded warrants", "documentation": "Number of warrants issued.", "label": "Number Of Warrants Issued" } } }, "auth_ref": [] }, "pbm_NumberOfWarrantsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfWarrantsOutstanding", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails", "http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable", "http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Warrants, Beginning", "periodEndLabel": "Number of Warrants, Ending", "terseLabel": "Number of Warrants, Ending", "verboseLabel": "Number of Warrants Outstanding", "netLabel": "Purchase of common shares warrants", "documentation": "Number of warrants outstanding.", "label": "Number Of Warrants Outstanding" } } }, "auth_ref": [] }, "pbm_NumberOfWarrantsSharesEndingBalanceinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfWarrantsSharesEndingBalanceinShares", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Warrants, Ending Balance", "documentation": "Number of warrants shares ending balance.", "label": "Number Of Warrants Shares Ending Balancein Shares" } } }, "auth_ref": [] }, "pbm_NumberOfWarrantsSharesOpeningBalance": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "NumberOfWarrantsSharesOpeningBalance", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Warrants, Opening balance", "documentation": "Number of warrants shares opening balance.", "label": "Number Of Warrants Shares Opening Balance" } } }, "auth_ref": [] }, "pbm_OntarioSuperiorCourtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "OntarioSuperiorCourtMember", "presentation": [ "http://www.psyencebiomed.com/role/OtherExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ontario Superior Court [Member]", "label": "Ontario Superior Court Member" } } }, "auth_ref": [] }, "ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation [Member]", "label": "Opening balance after adjustment, cumulative effect at date of initial application [member]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofChangeinPresentationCurrencyTable" ], "lang": { "en-us": { "role": { "label": "Opening balance before adjustment, cumulative effect at date of initial application [member]" } } }, "auth_ref": [ "r334" ] }, "ifrs-full_OperatingCategoryInProfitOrLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingCategoryInProfitOrLossAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other items", "label": "Operating category in profit or loss [abstract]" } } }, "auth_ref": [] }, "pbm_OptionsReserveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "OptionsReserveMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Options Reserve", "label": "Options Reserve Member" } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/ELOCDetails", "http://www.psyencebiomed.com/role/OtherExpenseDetails", "http://www.psyencebiomed.com/role/PromissoryNotesDetails", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails", "http://www.psyencebiomed.com/role/ShareCapitalDetails", "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares", "verboseLabel": "Common Shares [Member]", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r340" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "label": "Other Income [Abstract]", "terseLabel": "Other comprehensive income/(loss)" } } }, "auth_ref": [] }, "pbm_OtherComprehensiveIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "OtherComprehensiveIncomeLoss", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income", "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognized in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]", "label": "Other Comprehensive Income Loss" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign exchange gain/(loss) on translation", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r240", "r249" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r283", "r284" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other current receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r276", "r281" ] }, "ifrs-full_OtherExpenseByFunction": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherExpenseByFunction", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Other expense", "label": "Other expense, by function" } } }, "auth_ref": [ "r30", "r251", "r279" ] }, "ifrs-full_OtherExpenseByNature": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherExpenseByNature", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/OtherExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total net settlement expense", "label": "Other expenses, by nature" } } }, "auth_ref": [ "r251", "r278" ] }, "pbm_OtherExpenseDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "OtherExpenseDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/OtherExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Other Expense (Details) [Table]" } } }, "auth_ref": [] }, "pbm_OtherExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "OtherExpenseLineItems", "presentation": [ "http://www.psyencebiomed.com/role/OtherExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Other Expense [Line Items]" } } }, "auth_ref": [] }, "ifrs-full_OtherFeeAndCommissionExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherFeeAndCommissionExpense", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ELOCDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment fee", "label": "Other fee and commission expense" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement", "http://www.psyencebiomed.com/role/OtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "label": "Other income" } } }, "auth_ref": [ "r29", "r278", "r279" ] }, "pbm_OtherIncomeDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "OtherIncomeDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/OtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Other Income (Details) [Table]" } } }, "auth_ref": [] }, "pbm_OtherIncomeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "OtherIncomeLineItems", "presentation": [ "http://www.psyencebiomed.com/role/OtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Other Income [Line Items]" } } }, "auth_ref": [] }, "pbm_OtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "OtherReceivablesMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables [Member]", "label": "Other Receivables Member" } } }, "auth_ref": [] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Reserves", "label": "Other reserves" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r277", "r282" ] }, "ifrs-full_OtherTemporaryDifferencesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherTemporaryDifferencesMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted interest and financing expenses [Member]", "label": "Other temporary differences [member]" } }, "en": { "role": { "documentation": "This member stands for temporary differences that the entity does not separately disclose in the same statement or note. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r316" ] }, "pbm_OwnedAmountOfService": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "OwnedAmountOfService", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Owned amount of service (in Dollars)", "documentation": "Owned amount of service.", "label": "Owned Amount Of Service" } } }, "auth_ref": [] }, "pbm_PBMMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PBMMember", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PBM [Member]", "label": "PBMMember" } } }, "auth_ref": [] }, "pbm_PGIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PGIMember", "presentation": [ "http://www.psyencebiomed.com/role/PromissoryNotesDetails", "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PGI [Member]", "label": "PGIMember" } } }, "auth_ref": [] }, "pbm_PIPEFinancingPrivatePlacementAndWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PIPEFinancingPrivatePlacementAndWarrantsAbstract", "lang": { "en-us": { "role": { "label": "PIPE Financing - Private Placement and Warrants [Abstract]" } } }, "auth_ref": [] }, "pbm_PIPEFinancingPrivatePlacementAndWarrantsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PIPEFinancingPrivatePlacementAndWarrantsLineItems", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "PIPE Financing - Private Placement and Warrants [Line Items]" } } }, "auth_ref": [] }, "pbm_PIPEFinancingPrivatePlacementandWarrantsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PIPEFinancingPrivatePlacementandWarrantsDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "PIPE Financing - Private Placement and Warrants (Details) [Table]" } } }, "auth_ref": [] }, "pbm_PIPEFinancingPrivatePlacementandWarrantsScheduleofFairValueAllocationDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PIPEFinancingPrivatePlacementandWarrantsScheduleofFairValueAllocationDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable" ], "lang": { "en-us": { "role": { "label": "PIPE Financing - Private Placement and Warrants - Schedule of Fair Value Allocation (Details) [Table]" } } }, "auth_ref": [] }, "pbm_PIPEFinancingPrivatePlacementandWarrantsScheduleofPrefundedWarrantsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PIPEFinancingPrivatePlacementandWarrantsScheduleofPrefundedWarrantsDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "label": "PIPE Financing - Private Placement and Warrants - Schedule of Pre-funded Warrants (Details) [Table]" } } }, "auth_ref": [] }, "pbm_PaidAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PaidAmount", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/OtherExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement paid amount", "documentation": "The amount of paid amount.", "label": "Paid Amount" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails", "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails", "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable", "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of the common shares (in Dollars per share)", "verboseLabel": "Price per share", "netLabel": "Price per share (in Dollars per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r147", "r216", "r242" ] }, "ifrs-full_ParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParentMember", "presentation": [ "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Parent [member]", "label": "Parent [member]" } }, "en": { "role": { "documentation": "This member stands for an entity that controls one or more entities." } } }, "auth_ref": [ "r25", "r177" ] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/OtherExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Obligation to pay (in Dollars)", "label": "Payments for share issue costs" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r324" ] }, "pbm_PercentageOfOutstandingShares": { "xbrltype": "percentItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PercentageOfOutstandingShares", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of outstanding shares", "documentation": "Represents the percentage of outstanding shares.", "label": "Percentage Of Outstanding Shares" } } }, "auth_ref": [] }, "pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption": { "xbrltype": "percentItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PercentageOfReasonablyPossibleChangeInRiskAssumption", "presentation": [ "http://www.psyencebiomed.com/role/FinancialInstrumentsandFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fluctuation in foreign exchange rate", "documentation": "The reasonably possible percentage of the change in the designated risk component used to determine the value of the financial instrument. Excludes defined benefit plan obligations.", "label": "Percentage Of Reasonably Possible Change In Risk Assumption" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfVotingEquityInterestsAcquired", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of equity method post acquisition", "label": "Percentage of voting equity interests acquired" } }, "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r108", "r200" ] }, "pbm_PercentageOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PercentageOwnershipInterest", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of ownership interest", "documentation": "The percentage of ownership interest.", "label": "Percentage Ownership Interest" } } }, "auth_ref": [] }, "pbm_PpurchasePricePerShares": { "xbrltype": "perShareItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PpurchasePricePerShares", "presentation": [ "http://www.psyencebiomed.com/role/LoanReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price per shares (in Dollars per share)", "documentation": "Purchase price per shares.", "label": "Ppurchase Price Per Shares" } } }, "auth_ref": [] }, "pbm_PrefundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PrefundedWarrants", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable": { "parentTag": "pbm_FairValueAllocationGrossProceeds", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails", "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-funded warrants", "documentation": "It represents fair value of allocated pre funded warrants.", "label": "Prefunded Warrants" } } }, "auth_ref": [] }, "pbm_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PrefundedWarrantsMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-funded warrants [Member]", "label": "Prefunded Warrants Member" } } }, "auth_ref": [] }, "ifrs-full_PrepaymentsAndAccruedIncomeOtherThanContractAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PrepaymentsAndAccruedIncomeOtherThanContractAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Prepaid Expenses [Abstract]" } } }, "auth_ref": [] }, "pbm_PreviouslyHeldInterestRemeasuredToFairValueAtAcquisitionDateShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PreviouslyHeldInterestRemeasuredToFairValueAtAcquisitionDateShares", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingAmountofInvestmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Previously held interest \u2013 remeasured to fair value at Acquisition Date, Shares (in Shares)", "documentation": "The number of previously held interest remeasured to fair value at acquisition date, shares.", "label": "Previously Held Interest Remeasured To Fair Value At Acquisition Date Shares" } } }, "auth_ref": [] }, "pbm_PrivatePlacementAndWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PrivatePlacementAndWarrantsMember", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement and Warrants [Member]", "label": "Private Placement And Warrants Member" } } }, "auth_ref": [] }, "pbm_PrivateWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PrivateWarrantsMember", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Private Warrants [Member]", "documentation": "This member stands for private warrants.", "label": "Private Warrants Member" } } }, "auth_ref": [] }, "pbm_ProceedsFromContributionsOfParent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ProceedsFromContributionsOfParent", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds received from convertible note", "documentation": "The amount of proceeds from contributions of parent.", "label": "Proceeds From Contributions Of Parent" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants valued", "label": "Proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r324" ] }, "pbm_ProceedsFromIssuanceOfFinancingDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ProceedsFromIssuanceOfFinancingDebt", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from convertible debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds From Issuance Of Financing Debt" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow", "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share of losses from Associate", "verboseLabel": "Common shares valued", "label": "Proceeds from issue of ordinary shares" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r324" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds received for unit issuances", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r256" ] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Professional and consulting fees", "label": "Professional fees expense" } } }, "auth_ref": [ "r335" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow", "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement", "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable", "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME/(LOSS)", "terseLabel": "Net profit (loss) for the year", "verboseLabel": "Net (loss)/profit", "netLabel": "Net Income/(Loss) before recovery of income taxes", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r66", "r69", "r132", "r133", "r180", "r191", "r223", "r245", "r259", "r265" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before other items", "label": "Profit (loss) before tax" } } }, "auth_ref": [ "r113", "r272", "r273", "r278", "r279" ] }, "pbm_PromissoryNotesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PromissoryNotesAbstract", "lang": { "en-us": { "role": { "label": "Promissory Notes [Abstract]" } } }, "auth_ref": [] }, "pbm_PromissoryNotesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PromissoryNotesDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "label": "Promissory Notes (Details) [Table]" } } }, "auth_ref": [] }, "pbm_PromissoryNotesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PromissoryNotesTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/PromissoryNotes" ], "lang": { "en-us": { "role": { "terseLabel": "Promissory Notes", "documentation": "The entire disclosure on promissory notes.", "label": "Promissory Notes Text Block" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "http://www.psyencebiomed.com/role/ScheduleofEquipmentTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "terseLabel": "Equipment", "label": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r12", "r170", "r229" ] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Equipment [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "% ownership", "label": "Proportion of ownership interest in subsidiary" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r34", "r37", "r72" ] }, "pbm_PsyenceAustraliaPtyLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PsyenceAustraliaPtyLtdMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Psyence Australia Pty Ltd. [Member]", "label": "Psyence Australia Pty Ltd Member" } } }, "auth_ref": [] }, "pbm_PsyenceLabsLtdInvestmentandInvestmentinAssociateDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PsyenceLabsLtdInvestmentandInvestmentinAssociateDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "label": "Psyence Labs Ltd. Investment and Investment in Associate (Details) [Table]" } } }, "auth_ref": [] }, "pbm_PsyenceLabsLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PsyenceLabsLtdMember", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Psyence Labs Ltd. [Member]", "label": "Psyence Labs Ltd Member" } } }, "auth_ref": [] }, "pbm_PublicWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PublicWarrantsMember", "presentation": [ "http://www.psyencebiomed.com/role/DerivativeWarrantLiabilitiesDetails", "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable", "http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Public Warrants [Member]", "verboseLabel": "Derivative warrant liabilities \u2013 public warrants [Member]", "documentation": "This member stands for public warrants.", "label": "Public Warrants Member" } } }, "auth_ref": [] }, "pbm_PurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PurchaseAgreement", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ELOCDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase agreement", "documentation": "The amount of purchase agreement.", "label": "Purchase Agreement" } } }, "auth_ref": [] }, "pbm_PurchaseOfCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PurchaseOfCommonShares", "presentation": [ "http://www.psyencebiomed.com/role/OtherExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of common shares (in Shares)", "documentation": "The number of common shares purchase.", "label": "Purchase Of Common Shares" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment in Psyence Labs Ltd", "label": "Purchase of interests in investments accounted for using equity method" } }, "en": { "role": { "documentation": "The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } } }, "auth_ref": [ "r323" ] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Additions to equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r255" ] }, "pbm_PurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PurchasePricePerShare", "presentation": [ "http://www.psyencebiomed.com/role/OtherExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price per share (in Dollars per share)", "documentation": "Purchase price per common shares.", "label": "Purchase Price Per Share" } } }, "auth_ref": [] }, "pbm_PurchaseValueOfCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PurchaseValueOfCommonShares", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/OtherExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase value of common shares", "documentation": "The amount of purchase value of common shares.", "label": "Purchase Value Of Common Shares" } } }, "auth_ref": [] }, "pbm_PysenceBiomedIICorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "PysenceBiomedIICorpMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Pysence Biomed II Corp. [Member]", "documentation": "This member stands for Pysence Biomed II Corp.", "label": "Pysence Biomed IICorp Member" } } }, "auth_ref": [] }, "pbm_QuantityOfDigitalAssets": { "xbrltype": "decimalItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "QuantityOfDigitalAssets", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Quantity", "documentation": "Number of quantity.", "label": "Quantity Of Digital Assets" } } }, "auth_ref": [] }, "pbm_RTOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "RTOMember", "presentation": [ "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RTO [Member]", "label": "RTOMember" } } }, "auth_ref": [] }, "pbm_RTOTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "RTOTransactionMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RTO Transaction [Member]", "label": "RTOTransaction Member" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r55", "r86", "r92", "r102", "r150", "r262", "r263", "r331" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r55", "r86", "r92", "r102", "r150", "r262", "r263", "r331" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Canadian Federal and Provincial Statutory Income Tax Rate [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Transactions with Related Parties [Abstract]" } } }, "auth_ref": [] }, "pbm_RemeasuredCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "RemeasuredCarryingAmount", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasured carrying amount", "documentation": "The amount of remeasured carrying amount.", "label": "Remeasured Carrying Amount" } } }, "auth_ref": [] }, "pbm_RemeasurementOfPreviouslyHeldInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "RemeasurementOfPreviouslyHeldInterestMember", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasurement of Previously Held Interest [Member]", "label": "Remeasurement Of Previously Held Interest Member" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBondsNotesAndDebentures": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBondsNotesAndDebentures", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of promissory note", "label": "Repayments of bonds, notes and debentures" } }, "en": { "role": { "documentation": "The cash outflow for repayments of bonds, notes and debentures." } } }, "auth_ref": [ "r324" ] }, "ifrs-full_RepaymentsOfCurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfCurrentBorrowings", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes paid", "label": "Repayments of current borrowings" } }, "en": { "role": { "documentation": "The cash outflow for repayments of current borrowings. [Refer: Current borrowings]" } } }, "auth_ref": [ "r324" ] }, "pbm_ResearchAndDevelopmentExpenditurePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ResearchAndDevelopmentExpenditurePercentage", "presentation": [ "http://www.psyencebiomed.com/role/MaterialAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of research and development expenditures", "documentation": "Percentage of research and development expenditures.", "label": "Research And Development Expenditure Percentage" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and development expense" } } }, "auth_ref": [ "r47", "r184" ] }, "pbm_ResearchAndDevelopmentExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ResearchAndDevelopmentExpensesMember", "presentation": [ "http://www.psyencebiomed.com/role/OtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expenses [Member]", "label": "Research And Development Expenses Member" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Reserves", "label": "Reserve of exchange differences on translation [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r20", "r174", "r280" ] }, "ifrs-full_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCashandCashEquivalentsTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Restricted cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r337" ] }, "pbm_RestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "RestrictedCashMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofClassificationandMeasurementsofFinancialAssetsandLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash [Member]", "label": "Restricted Cash Member" } } }, "auth_ref": [] }, "ifrs-full_RestrictedShareUnitsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestrictedShareUnitsMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofRestrictedStockUnitsTable", "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs [Member]", "label": "Restricted share units [member]" } }, "en": { "role": { "documentation": "This member stands for restricted share units." } } }, "auth_ref": [ "r319" ] }, "pbm_RestrictedStockUnitsRSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "RestrictedStockUnitsRSUsMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs) [Member]", "label": "Restricted Stock Units RSUs Member" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r277", "r282", "r284" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r225", "r280" ] }, "pbm_RevaluationDecreaseOfDigitalAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "RevaluationDecreaseOfDigitalAsset", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Revaluation Decrease", "documentation": "Amount of revaluation decrease.", "label": "Revaluation Decrease Of Digital Asset" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromInterest", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest income" } }, "en": { "role": { "documentation": "The amount of income arising from interest." } } }, "auth_ref": [ "r77", "r128", "r136", "r335" ] }, "ifrs-full_ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/CashRestrictedCashandCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deposit made in a guaranteed investment certificate with the bank", "label": "Reverse repurchase agreements and cash collateral on securities borrowed" } }, "en": { "role": { "documentation": "The amount of instruments purchased for resale in reverse repurchase agreements and cash collateral on securities borrowed. [Refer: Repurchase agreements and cash collateral on securities lent]" } } }, "auth_ref": [ "r337" ] }, "pbm_ReverseTakeoverTransactionWithNCACAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ReverseTakeoverTransactionWithNCACAbstract", "lang": { "en-us": { "role": { "label": "Reverse Takeover Transaction with NCAC [Abstract]" } } }, "auth_ref": [] }, "pbm_ReverseTakeoverTransactionWithNCACLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ReverseTakeoverTransactionWithNCACLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails" ], "lang": { "en-us": { "role": { "label": "Reverse Takeover Transaction with NCAC [Line Items]" } } }, "auth_ref": [] }, "pbm_ReverseTakeoverTransactionWithNcacAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ReverseTakeoverTransactionWithNcacAxis", "presentation": [ "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Takeover Transaction with NCAC [Axis]", "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.", "label": "Reverse Takeover Transaction With Ncac Axis" } } }, "auth_ref": [] }, "pbm_ReverseTakeoverTransactionWithNcacTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ReverseTakeoverTransactionWithNcacTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCAC" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse takeover transaction with NCAC", "documentation": "Reverse takeover transaction with NCAC", "label": "Reverse Takeover Transaction With Ncac Text Block" } } }, "auth_ref": [] }, "pbm_ReverseTakeoverTransactionwithNCACDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ReverseTakeoverTransactionwithNCACDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails" ], "lang": { "en-us": { "role": { "label": "Reverse Takeover Transaction with NCAC (Details) [Table]" } } }, "auth_ref": [] }, "pbm_ReverseTakeoverTransactionwithNCACScheduleofListingExpensesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ReverseTakeoverTransactionwithNCACScheduleofListingExpensesDetailsLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable" ], "lang": { "en-us": { "role": { "label": "Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details) [Line Items]" } } }, "auth_ref": [] }, "pbm_ReverseTakeoverTransactionwithNCACScheduleofListingExpensesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ReverseTakeoverTransactionwithNCACScheduleofListingExpensesDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable" ], "lang": { "en-us": { "role": { "label": "Reverse Takeover Transaction with NCAC - Schedule of Listing Expenses (Details) [Table]" } } }, "auth_ref": [] }, "pbm_RiskfreeInterestRateWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "RiskfreeInterestRateWarrantMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate [Member]", "label": "Riskfree Interest Rate Warrant Member" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Sales and marketing expense" } } }, "auth_ref": [ "r341" ] }, "pbm_ScheduleOfCarryingAmountOfInvestmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfCarryingAmountOfInvestmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Carrying Amount of Investment [Abstract]" } } }, "auth_ref": [] }, "pbm_ScheduleOfCarryingAmountOfInvestmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfCarryingAmountOfInvestmentTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Amount of Investment", "documentation": "The tabular disclosure of carrying amount of investment.", "label": "Schedule Of Carrying Amount Of Investment Table Text Block" } } }, "auth_ref": [] }, "pbm_ScheduleOfCarryingValueOfTheFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfCarryingValueOfTheFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Carrying Value Of The Financial Instruments Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfChangeInPresentationCurrencyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfChangeInPresentationCurrencyAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Change In Presentation Currency Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Classification And Measurements Of Financial Assets And Liabilities Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfClassificationAndMeasurementsOfFinancialAssetsAndLiabilitiesTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/MaterialAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Classification and Measurements of Financial Assets and Liabilities", "documentation": "The description of the entity's classification and measurements of financial assets and liabilities.", "label": "Schedule Of Classification And Measurements Of Financial Assets And Liabilities Text Block" } } }, "auth_ref": [] }, "pbm_ScheduleOfDigitalAssetHoldingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfDigitalAssetHoldingsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Digital Asset Holdings Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationsTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/IncomeTaxNoteTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Canadian Federal and Provincial Statutory Income Tax Rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliations Table Text Block" } } }, "auth_ref": [] }, "pbm_ScheduleOfEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Equipment Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfFairValueAllocationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfFairValueAllocationAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Fair Value Allocation Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfFairValueAllocationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfFairValueAllocationLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value Allocation [Line Items]" } } }, "auth_ref": [] }, "pbm_ScheduleOfIssuedAndOutstandingCommonSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfIssuedAndOutstandingCommonSharesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Issued And Outstanding Common Shares Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfIssuedAndOutstandingCommonSharesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfIssuedAndOutstandingCommonSharesLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Issued and Outstanding Common Shares [Line Items]" } } }, "auth_ref": [] }, "pbm_ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfIssuedAndOutstandingCommonSharesTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Issued and Outstanding Common Shares", "documentation": "Tabular disclosure of issued and outstanding common shares.", "label": "Schedule Of Issued And Outstanding Common Shares Table Text Block" } } }, "auth_ref": [] }, "pbm_ScheduleOfIssuedAndOutstandingWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfIssuedAndOutstandingWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Issued and Outstanding Warrants [Abstract]" } } }, "auth_ref": [] }, "pbm_ScheduleOfIssuedAndOutstandingWarrantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfIssuedAndOutstandingWarrantsTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Issued and Outstanding Warrants", "documentation": "Tabular disclosure of issued and outstanding warrants.", "label": "Schedule Of Issued And Outstanding Warrants Table Text Block" } } }, "auth_ref": [] }, "pbm_ScheduleOfListingExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfListingExpensesTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Listing Expenses", "documentation": "The tabular disclosure of calculation of listing expenses.", "label": "Schedule Of Listing Expenses Table Text Block" } } }, "auth_ref": [] }, "pbm_ScheduleOfLoanProceedsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfLoanProceedsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Loan Proceeds [Abstract]" } } }, "auth_ref": [] }, "pbm_ScheduleOfMaturityOfTheContractualObligationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfMaturityOfTheContractualObligationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Maturity Of The Contractual Obligations Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfNonCapitalLossCarryForwardsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfNonCapitalLossCarryForwardsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Non Capital Loss Carry Forwards Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfPreFundedWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfPreFundedWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Pre Funded Warrants Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfPrivateWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfPrivateWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Private Warrants Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfRestrictedStockUnitsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfRestrictedStockUnitsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Restricted Stock Units Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfRestrictedStockUnitsRSUsTableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfRestrictedStockUnitsRSUsTableTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Units", "documentation": "The entire tabular disclosure of restricted stock units (RSUs).", "label": "Schedule Of Restricted Stock Units RSUs Table Table Text Block" } } }, "auth_ref": [] }, "pbm_ScheduleOfSubsidiariesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfSubsidiariesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Subsidiaries Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfTotalManagedCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfTotalManagedCapitalAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Total Managed Capital [Abstract]" } } }, "auth_ref": [] }, "pbm_ScheduleOfUnrecognizedDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfUnrecognizedDeferredTaxAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Unrecognized Deferred Tax Assets Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfUsingTheBlackScholesPricingModelAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfUsingTheBlackScholesPricingModelAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Using The Black Scholes Pricing Model Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfWarrantTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfWarrantTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrant Transactions Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfWarrantsOutstandingAndExercisableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfWarrantsOutstandingAndExercisableAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrants Outstanding And Exercisable Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfWarrantsWereOutstandingAndExercisableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfWarrantsWereOutstandingAndExercisableAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrants Were Outstanding And Exercisable Abstract" } } }, "auth_ref": [] }, "pbm_ScheduleOfWarrantsWereOutstandingAndExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ScheduleOfWarrantsWereOutstandingAndExercisableTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrants were Outstanding and Exercisable", "documentation": "Tabular disclosure of Warrants were outstanding and exercisable.", "label": "Schedule Of Warrants Were Outstanding And Exercisable Table Text Block" } } }, "auth_ref": [] }, "pbm_SecondTrancheNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "SecondTrancheNotesMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Tranche Notes [Member]", "label": "Second Tranche Notes Member" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r286" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r288" ] }, "pbm_ShareCapitalDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ShareCapitalDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Share Capital (Details) [Table]" } } }, "auth_ref": [] }, "pbm_ShareCapitalScheduleofIssuedandOutstandingCommonSharesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ShareCapitalScheduleofIssuedandOutstandingCommonSharesDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingCommonSharesTable" ], "lang": { "en-us": { "role": { "label": "Share Capital - Schedule of Issued and Outstanding Common Shares (Details) [Table]" } } }, "auth_ref": [] }, "pbm_ShareCapitalScheduleofRestrictedStockUnitsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ShareCapitalScheduleofRestrictedStockUnitsDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofRestrictedStockUnitsTable" ], "lang": { "en-us": { "role": { "label": "Share Capital - Schedule of Restricted Stock Units (Details) [Table]" } } }, "auth_ref": [] }, "pbm_ShareCapitalScheduleofWarrantswereOutstandingandExercisableDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ShareCapitalScheduleofWarrantswereOutstandingandExercisableDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "label": "Share Capital - Schedule of Warrants were Outstanding and Exercisable (Details) [Table]" } } }, "auth_ref": [] }, "pbm_ShareIssuanceCostsAndOthersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ShareIssuanceCostsAndOthersMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share issuance costs and others [Member]", "label": "Share Issuance Costs And Others Member" } } }, "auth_ref": [] }, "pbm_ShareIssueCostsBookedToEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ShareIssueCostsBookedToEquity", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Share issue costs booked to equity", "documentation": "Share issue costs booked to equity.", "label": "Share Issue Costs Booked To Equity" } } }, "auth_ref": [] }, "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails", "http://www.psyencebiomed.com/role/ScheduleofCarryingAmountofInvestmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share of losses from Associate", "verboseLabel": "Share of associate net loss \u2013 February 25 to March 31, 2026", "netLabel": "Net loss", "label": "Share of profit (loss) of associates and joint ventures accounted for using equity method, investing" } } }, "auth_ref": [ "r130", "r136", "r247" ] }, "pbm_SharePriceMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "SharePriceMeasurementInputMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share price [Member]", "documentation": "This member stands for share price used as a measurement input.", "label": "Share Price Measurement Input Member" } } }, "auth_ref": [] }, "pbm_SharePriceWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "SharePriceWarrantMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share price [Member]", "label": "Share Price Warrant Member" } } }, "auth_ref": [] }, "pbm_ShareSettledIssuanceCostsCostsSettled": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ShareSettledIssuanceCostsCostsSettled", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash settled share issuance costs", "documentation": "The amount of share settled issuance costs settled during the period.", "label": "Share Settled Issuance Costs Costs Settled" } } }, "auth_ref": [] }, "pbm_ShareWarrantIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ShareWarrantIssued", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share warrant issued", "documentation": "Share warrant issued.", "label": "Share Warrant Issued" } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermBorrowings", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofLoanProceedsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Current borrowings" } }, "en": { "role": { "documentation": "The amount of current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r337" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofSubsidiariesTable" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r35", "r38", "r80", "r211" ] }, "pbm_SignificantUnobservableInputEntitysOwnEquityInstrument": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "SignificantUnobservableInputEntitysOwnEquityInstrument", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, measurement input", "verboseLabel": "Fair value of pre-funded warrants", "documentation": "The value of significant unobservable input used in the measurement of the fair value of entity's own equity instruments.", "label": "Significant Unobservable Input Entitys Own Equity Instrument" } } }, "auth_ref": [] }, "ifrs-full_SignificantUnobservableInputEntitysOwnEquityInstruments": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantUnobservableInputEntitysOwnEquityInstruments", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of pre-funded warrants", "label": "Significant unobservable input, entity's own equity instruments" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of entity's own equity instruments." } } }, "auth_ref": [ "r83" ] }, "ifrs-full_SignificantUnobservableInputLiabilities": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantUnobservableInputLiabilities", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, measurement input", "verboseLabel": "Measured the fair value inputs", "label": "Significant unobservable input, liabilities" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } } }, "auth_ref": [ "r83" ] }, "pbm_SolanaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "SolanaMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Solana [Member]", "label": "Solana Member" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r225" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodShareIssuanceOfUnitsForPIPEFinancingNetOfIssuanceCostsinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodShareIssuanceOfUnitsForPIPEFinancingNetOfIssuanceCostsinShares", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of units for PIPE financing, net of issuance costs (in Shares)", "documentation": "Number of shares issuance of units for PIPE financing, net of issuance costs.", "label": "Stock Issued During Period Share Issuance Of Units For PIPEFinancing Net Of Issuance Costsin Shares" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodShareStockSplits": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodShareStockSplits", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of stock split", "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.", "label": "Stock Issued During Period Share Stock Splits" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForConvertibleNoteinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForConvertibleNoteinShares", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for convertible note (in Shares)", "documentation": "Number of shares Issuance of shares for convertible note.", "label": "Stock Issued During Period Shares Issuance Of Shares For Convertible Notein Shares" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForDebtSettlement": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForDebtSettlement", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for debt settlement (in Shares)", "documentation": "Number of issuance of shares for debt settlement.", "label": "Stock Issued During Period Shares Issuance Of Shares For Debt Settlement" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForELOCNetOfIssuanceCostsinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForELOCNetOfIssuanceCostsinShares", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for ELOC, net of issuance costs (in Shares)", "documentation": "Number of shares issuance of shares for ELOC, net of issuance costs.", "label": "Stock Issued During Period Shares Issuance Of Shares For ELOCNet Of Issuance Costsin Shares" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForPromissoryNotesinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForPromissoryNotesinShares", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for promissory notes (in Shares)", "documentation": "Number of shares issuance of shares for promissory notes.", "label": "Stock Issued During Period Shares Issuance Of Shares For Promissory Notesin Shares" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForPsyenceLabsLtdSharesinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForPsyenceLabsLtdSharesinShares", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for Psyence Labs Ltd shares (in Shares)", "documentation": "Number of shares issuance of shares for psyence labs ltd shares.", "label": "Stock Issued During Period Shares Issuance Of Shares For Psyence Labs Ltd Sharesin Shares" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantConversioninShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantConversioninShares", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for warrant conversion (in Shares)", "documentation": "Number of shares issuance of shares for warrant conversion.", "label": "Stock Issued During Period Shares Issuance Of Shares For Warrant Conversionin Shares" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchange": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchange", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Warrants, Warrant exchange", "documentation": "Represent the stock issued during period shares issuance of shares for warrant exchange.", "label": "Stock Issued During Period Shares Issuance Of Shares For Warrant Exchange" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchangeinShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchangeinShares", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for warrant exchange (in Shares)", "documentation": "Number of shares issuance of shares for warrant exchange.", "label": "Stock Issued During Period Shares Issuance Of Shares For Warrant Exchangein Shares" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchanges": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesForWarrantExchanges", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares, Warrant exchange", "documentation": "Number of shares issuance of shares for warrant exchange.", "label": "Stock Issued During Period Shares Issuance Of Shares For Warrant Exchanges" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesToNCACShareholders": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesToNCACShareholders", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares to NCAC shareholders (in Shares)", "documentation": "Number of issuance of shares to NCAC shareholders.", "label": "Stock Issued During Period Shares Issuance Of Shares To NCACShareholders" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesToPsyenceGroupInc": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesToPsyenceGroupInc", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares to Psyence Group Inc (in Shares)", "documentation": "Number of issuance of shares to Psyence Group Inc.", "label": "Stock Issued During Period Shares Issuance Of Shares To Psyence Group Inc" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuanceOfSharesToThirdPartyAdvisors": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesToThirdPartyAdvisors", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares to third party advisors (in Shares)", "documentation": "Number of issuance of shares to third party advisors.", "label": "Stock Issued During Period Shares Issuance Of Shares To Third Party Advisors" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued to NCAC shareholders (in Shares)", "documentation": "Number of stock issued during the period for reverse takeover transaction.", "label": "Stock Issued During Period Shares Issued For Reverse Takeover Transaction" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodSharesNewIssue": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodSharesNewIssue", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares", "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issue" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForConvertibleNote", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for convertible note", "documentation": "Represent the amount of issuance of shares for convertible note.", "label": "Stock Issued During Period Value Issuance Of Shares For Convertible Note" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForDebtSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForDebtSettlement", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for debt settlement", "documentation": "Value of issuance of shares for debt settlement.", "label": "Stock Issued During Period Value Issuance Of Shares For Debt Settlement" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForELOCNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForELOCNetOfIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for ELOC, net of issuance costs", "documentation": "Represent the amount of issuance of shares for ELOC, net of issuance costs.", "label": "Stock Issued During Period Value Issuance Of Shares For ELOCNet Of Issuance Costs" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForInvestmentInAssociate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForInvestmentInAssociate", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for investment in Associate", "documentation": "Issuance of shares for investment in Associate.", "label": "Stock Issued During Period Value Issuance Of Shares For Investment In Associate" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForPromissoryNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForPromissoryNotes", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for promissory notes", "documentation": "Represent the amount of issuance of shares for promissory notes.", "label": "Stock Issued During Period Value Issuance Of Shares For Promissory Notes" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForPsyenceLabsLtdShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForPsyenceLabsLtdShares", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for Psyence Labs Ltd shares", "documentation": "Represent the amount of issuance of shares for Psyence Labs Ltd shares.", "label": "Stock Issued During Period Value Issuance Of Shares For Psyence Labs Ltd Shares" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodValueIssuanceOfSharesForWarrantExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForWarrantExchange", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares for warrant exchange", "documentation": "Represent the amount of issuance of shares for warrant exchange.", "label": "Stock Issued During Period Value Issuance Of Shares For Warrant Exchange" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodValueIssuanceOfSharesToNCACShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesToNCACShareholders", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares to NCAC shareholders", "documentation": "Value of issuance of shares to NCAC shareholders.", "label": "Stock Issued During Period Value Issuance Of Shares To NCACShareholders" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodValueIssuanceOfSharesToThirdPartyAdvisors": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesToThirdPartyAdvisors", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares to third party advisors", "documentation": "Value of issuance of shares to third party advisors.", "label": "Stock Issued During Period Value Issuance Of Shares To Third Party Advisors" } } }, "auth_ref": [] }, "pbm_StockIssuedDuringPeriodValueIssuanceOfUnitsForPIPEFinancingNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "StockIssuedDuringPeriodValueIssuanceOfUnitsForPIPEFinancingNetOfIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of units for PIPE financing, net of issuance costs", "documentation": "Represent the amount of issuance of units for PIPE financing, net of issuance costs.", "label": "Stock Issued During Period Value Issuance Of Units For PIPEFinancing Net Of Issuance Costs" } } }, "auth_ref": [] }, "pbm_SubscriptionAgreementOfAdditionalShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "SubscriptionAgreementOfAdditionalShares", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional shares (in Shares)", "documentation": "Subscription agreement of additional shares.", "label": "Subscription Agreement Of Additional Shares" } } }, "auth_ref": [] }, "pbm_SubscriptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "SubscriptionAmount", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription amount", "documentation": "Represents the subscription amounts.", "label": "Subscription Amount" } } }, "auth_ref": [] }, "pbm_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "SubsequentEventsDetailsTable", "presentation": [ "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "auth_ref": [] }, "pbm_SubsequentEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "SubsequentEventsMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Member]", "label": "Subsequent Events Member" } } }, "auth_ref": [] }, "pbm_SummaryOfOperatingLossCarryForwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "SummaryOfOperatingLossCarryForwardsTableTextBlock", "presentation": [ "http://www.psyencebiomed.com/role/IncomeTaxNoteTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Non-Capital Loss Carry Forwards", "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carry forwards, including an assessment of the likelihood of utilization.", "label": "Summary Of Operating Loss Carry Forwards Table Text Block" } } }, "auth_ref": [] }, "pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TaxEffectFromChangeInTaxBenefitsNotRecognized", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Change in tax benefits not recognized", "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to change in tax benefits not recognized.", "label": "Tax Effect From Change In Tax Benefits Not Recognized" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfForeignTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxEffectOfForeignTaxRates", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Difference in foreign tax rates", "label": "Tax effect of foreign tax rates" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r162" ] }, "pbm_TaxEffectOflistingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TaxEffectOflistingExpense", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Listing expense", "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to listing expense.", "label": "Tax Effect Oflisting Expense" } } }, "auth_ref": [] }, "pbm_TaxEffectOfotherPermanentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TaxEffectOfotherPermanentExpenses", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Other permanent expenses", "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to other permanent expenses.", "label": "Tax Effect Ofother Permanent Expenses" } } }, "auth_ref": [] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCanadianFederalandProvincialStatutoryIncomeTaxRateTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected income tax (recovery)/expense", "label": "Tax expense (income) at applicable tax rate" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r3", "r162" ] }, "pbm_TaxYear2044Member": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TaxYear2044Member", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable" ], "lang": { "en-us": { "role": { "terseLabel": "2044 [Member]", "documentation": "Identified as tax year 2044.", "label": "Tax Year2044 Member" } } }, "auth_ref": [] }, "pbm_TaxYear2045Member": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TaxYear2045Member", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable" ], "lang": { "en-us": { "role": { "terseLabel": "2045 [Member]", "label": "Tax Year2045 Member" } } }, "auth_ref": [] }, "pbm_TaxYear2046Member": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TaxYear2046Member", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofNonCapitalLossCarryForwardsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Year 2046 [Member]", "label": "Tax Year2046 Member" } } }, "auth_ref": [] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r7", "r166" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofUnrecognizedDeferredTaxAssetsTable" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [domain]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r7", "r166" ] }, "pbm_TerminationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TerminationAgreementMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Agreement [Member]", "label": "Termination Agreement Member" } } }, "auth_ref": [] }, "pbm_TetherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TetherMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Tether [Member]", "label": "Tether Member" } } }, "auth_ref": [] }, "pbm_ThirdPartyAdvisorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ThirdPartyAdvisorsMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Party Advisors [Member]", "documentation": "This member stands for third party advisors.", "label": "Third Party Advisors Member" } } }, "auth_ref": [] }, "pbm_ThirdPartyAdvisorsShareIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ThirdPartyAdvisorsShareIssuance", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedCashFlow": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Third party advisors share issuance", "documentation": "Adjustments for third party advisors share issuance to reconcile operating profit (loss) to net cash flow from (used in) operating activities. [Refer: Operating profit (loss), operating]", "label": "Third Party Advisors Share Issuance" } } }, "auth_ref": [] }, "pbm_ThirdPartyInvestor": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "ThirdPartyInvestor", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third-party investor", "documentation": "Represent the amount of third-party investor.", "label": "Third Party Investor" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Top of range [Member]", "verboseLabel": "Top of Range [Member]", "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r55", "r86", "r92", "r102", "r150", "r262", "r263", "r331" ] }, "pbm_TotalInvestmentInAssociateAtAcquisitionDateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TotalInvestmentInAssociateAtAcquisitionDateAmount", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingAmountofInvestmentTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total \u2013 Investment in Associate at Acquisition Date, Amount", "documentation": "The amount of investments in associates acquisition date.", "label": "Total Investment In Associate At Acquisition Date Amount" } } }, "auth_ref": [] }, "pbm_TotalPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TotalPurchasePrice", "crdr": "credit", "presentation": [ "http://www.psyencebiomed.com/role/LoanReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total purchase price", "documentation": "Total purchase price.", "label": "Total Purchase Price" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable": { "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofListingExpensesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts payable and accrued liabilities", "label": "Trade and other current payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r231" ] }, "ifrs-full_TradeAndOtherPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayablesAbstract", "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable": { "parentTag": "pbm_CurrentAccountsPayableAndAccruedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofAccountsPayableandAccruedLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Trade payables" } }, "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } } }, "auth_ref": [ "r339" ] }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Loan Receivable [Abstract]" } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r303" ] }, "pbm_TradingPricePerShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TradingPricePerShares", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/CriticalAccountingEstimatesandJudgementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Closing trading price", "documentation": "Price of a single share of a number of closing trading price of a company.", "label": "Trading Price Per Shares" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "pbm_TransactionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "TransactionExpense", "crdr": "debit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement", "http://www.psyencebiomed.com/role/ReverseTakeoverTransactionwithNCACDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Transaction expense", "terseLabel": "Transaction expenses", "documentation": "The amount of transaction expense.", "label": "Transaction Expense" } } }, "auth_ref": [] }, "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfAntidilutiveInstrumentsAxis", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/ScheduleofRestrictedStockUnitsTable", "http://www.psyencebiomed.com/role/ShareCapitalDetails", "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Types of antidilutive instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r42" ] }, "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfAntidilutiveInstrumentsDomain", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/ShareCapitalDetails", "http://www.psyencebiomed.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Types of antidilutive instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used." } } }, "auth_ref": [ "r42" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r103", "r198" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r103", "r198" ] }, "pbm_USDCoinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "USDCoinMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDigitalAssetHoldingsTable" ], "lang": { "en-us": { "role": { "terseLabel": "USD Coin [Member]", "label": "USDCoin Member" } } }, "auth_ref": [] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable", "http://www.psyencebiomed.com/role/ScheduleofUsingtheBlackScholesPricingModelTable" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r83", "r329" ] }, "ifrs-full_UnobservableInputsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsDomain", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [domain]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r83", "r329" ] }, "pbm_UnrealizedFairValueGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "UnrealizedFairValueGain", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/PsyenceLabsLtdInvestmentandInvestmentinAssociateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized fair value gain", "documentation": "Represent the amount of unrealized fair value gain.", "label": "Unrealized Fair Value Gain" } } }, "auth_ref": [] }, "pbm_UnsecuredConvertiblePromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "UnsecuredConvertiblePromissoryNotesMember", "presentation": [ "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured Convertible Promissory Note [Member]", "documentation": "Represents information pertaining to unsecured convertible promissory note.", "label": "Unsecured Convertible Promissory Notes Member" } } }, "auth_ref": [] }, "pbm_WarrantExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantExchange", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofDerivativeWarrantLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount, Warrant exchange", "documentation": "The amount of Warrant exchange.", "label": "Warrant Exchange" } } }, "auth_ref": [] }, "pbm_WarrantExpiryDate": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantExpiryDate", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrivateWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant, expiry date", "documentation": "Warrant, expiry date.", "label": "Warrant Expiry Date" } } }, "auth_ref": [] }, "pbm_WarrantLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantLiabilitiesMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofCarryingValueoftheFinancialInstrumentsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant Liabilities [Member]", "documentation": "This member stands for warrant liabilities.", "label": "Warrant Liabilities Member" } } }, "auth_ref": [] }, "ifrs-full_WarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantLiability", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable": { "parentTag": "pbm_FairValueAllocationGrossProceeds", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofFairValueAllocationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrant liability" } }, "en": { "role": { "documentation": "The amount of warrant liabilities." } } }, "auth_ref": [ "r337" ] }, "ifrs-full_WarrantReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantReserve", "crdr": "credit", "calculation": { "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedBalanceSheet", "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants Reserve", "verboseLabel": "Warrant reserve", "label": "Warrant reserve" } }, "en": { "role": { "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]" } } }, "auth_ref": [ "r338" ] }, "pbm_WarrantSettledIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantSettledIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant settled issuance costs", "documentation": "The amount of share settled issuance costs settled during the period.", "label": "Warrant Settled Issuance Costs" } } }, "auth_ref": [] }, "pbm_WarrantTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantTransactionsLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Warrant Transactions [Line Items]" } } }, "auth_ref": [] }, "pbm_WarrantWith2YearExpiryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantWith2YearExpiryMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant with 2 year expiry [Member]", "label": "Warrant With2 Year Expiry Member" } } }, "auth_ref": [] }, "pbm_WarrantsAndRightsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantsAndRightsTerm", "presentation": [ "http://www.psyencebiomed.com/role/PIPEFinancingPrivatePlacementandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant outstanding term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants And Rights Term" } } }, "auth_ref": [] }, "pbm_WarrantsEachExercisableToPurchaseOneCommonShareAtAnExercisePriceOf4296328PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantsEachExercisableToPurchaseOneCommonShareAtAnExercisePriceOf4296328PerShareMember", "presentation": [ "http://www.psyencebiomed.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, each exercisable to purchase one Common Share at an exercise price of $42,963.28 per share", "label": "Warrants Each Exercisable To Purchase One Common Share At An Exercise Price Of4296328 Per Share Member" } } }, "auth_ref": [] }, "pbm_WarrantsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantsExercisePrice", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price (in Dollars per share)", "documentation": "Represent the exercise price of warrants.", "label": "Warrants Exercise Price" } } }, "auth_ref": [] }, "pbm_WarrantsExpiryDate": { "xbrltype": "dateItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantsExpiryDate", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantswereOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expiry Date", "documentation": "Represent the date of warrants expires.", "label": "Warrants Expiry Date" } } }, "auth_ref": [] }, "pbm_WarrantsIssuedForConvertibleNoteTerminationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantsIssuedForConvertibleNoteTerminationAgreement", "crdr": "debit", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofIssuedandOutstandingWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Warrants, Warrants issued for convertible note Termination Agreement (in Dollars)", "documentation": "The amount of warrants issued for convertible note termination agreement.", "label": "Warrants Issued For Convertible Note Termination Agreement" } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://www.psyencebiomed.com/role/ConvertibleNoteLiabilityDetails", "http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable", "http://www.psyencebiomed.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant [Member]", "verboseLabel": "Warrants [Member]", "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r319" ] }, "pbm_WarrantsOrRightsExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantsOrRightsExpirationDate", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expiry Date", "documentation": "Date which warrants or rights is set to expire, in YYYY-MM-DD format.", "label": "Warrants Or Rights Expiration Date" } } }, "auth_ref": [] }, "pbm_WarrantsOutstandingAndExercisableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantsOutstandingAndExercisableLineItems", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantsOutstandingandExercisableTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Warrants Outstanding and Exercisable [Line Items]" } } }, "auth_ref": [] }, "pbm_WarrantsReserveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantsReserveMember", "presentation": [ "http://www.psyencebiomed.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants Reserve", "label": "Warrants Reserve Member" } } }, "auth_ref": [] }, "pbm_WarrantsWith5YearExpiryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WarrantsWith5YearExpiryMember", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofPrefundedWarrantsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants with 5 year expiry [Member]", "label": "Warrants With5 Year Expiry Member" } } }, "auth_ref": [] }, "pbm_WeightedAverageExercisePriceWarrantExchange": { "xbrltype": "perShareItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WeightedAverageExercisePriceWarrantExchange", "presentation": [ "http://www.psyencebiomed.com/role/ScheduleofWarrantTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Warrant exchange", "documentation": "Represent the weighted average exercise price warrant exchange.", "label": "Weighted Average Exercise Price Warrant Exchange" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://www.psyencebiomed.com/role/PromissoryNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average share price (in Dollars per share)", "label": "Weighted average share price" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r101" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.psyencebiomed.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of outstanding shares - basic (in Shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r41" ] }, "pbm_WhiteLionCapitalLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WhiteLionCapitalLLCMember", "presentation": [ "http://www.psyencebiomed.com/role/ELOCDetails" ], "lang": { "en-us": { "role": { "terseLabel": "White Lion Capital, LLC [Member]", "label": "White Lion Capital LLCMember" } } }, "auth_ref": [] }, "pbm_WhiteLionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.psyencebiomed.com/20260331", "localname": "WhiteLionMember", "presentation": [ "http://www.psyencebiomed.com/role/ELOCDetails" ], "lang": { "en-us": { "role": { "terseLabel": "White Lion [Member]", "label": "White Lion Member" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "20", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19_a&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_46&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "48", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_48&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "29", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_29_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_29&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "49", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_49_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "30", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_30&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_b&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "19B", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_b&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B64", "Subparagraph": "p", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B64_p_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_g&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "128", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "170", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_170&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "171", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_171&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "178", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_178_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "179", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_179_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "179", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_179&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "184", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_184&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "186", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_186_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_e&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "216", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_216_a&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230_b&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231_a&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "274", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vii&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "34", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_c&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_35_e&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "43", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "56", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_56_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "88", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_88_a&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2026-01-01", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.49", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_l&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_r&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_c&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_d&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r272": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "191", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_191_f&doctype=Standard", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r277": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-X", "Number": "210", "Section": "2", "Subsection": "2" }, "r314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2025-03-27" }, "r330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }